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CHAPTER 1 
I N T R O D U C T I O N 
Patients with the same histological type of cancer do not respond uniformly 
to antineoplastic treatment Clinical experiences indicate that substantial 
heterogeneity exists within the same class of tumors. When patients with 
similar types of cancer are identically treated with currently available 
treatment modalities, some respond while others do not Variations in drug 
pharmacokinetics and metabolism maybe partly responsible for differences 
in responses among patients. In addition, there is evidence that tumors are 
heterogeneous in their cellular composition. 
It is clear that a patient-directed treatment may offer the best result 
Therefore, efforts are continuing in cancer research to develop human 
tumor models with the aim of testing possible therapeutic modalities and 
studying tumor biology. However, it is disappointing that clinicians still do 
not have appropriate models for the assessment of new treatment schemes 
and individual treatment modifications that can predict the response of the 
tumor in the patient situation to a certain regimen. In vivo models and in 
vitro assays may offer the possibility to study the response of human tumors 
to treatment The most essential question concerning xenograft tumor 
moüels is whether the tumor grafts do maintain the characteristics of the 
human source tumor in all aspects, including their therapeutic sensitivity. 
In this chapter, in vivo and in vitro methods will be reviewed as a prelude to 
stating the objectives of the experiments described in this thesis. 
1.1 IN VIVO MODELS FOR HUMAN TUMOR XENOGRAFTS. 
About twenty years ago, the major experiments on xenografting were 
performed in hamsters, new bom rats and mice and mice treated with 
antilymphocyte serum with or without neonatal thymectomy (36). In the 
early seventies, thymectomized, whole body irradiated and marrow recon-
stituted mice were used as recipients of xenogeneic tissues (8, 9). 
There was an improvement when cytosine arabinoside (200 mg. kg" ) was 
administered two days before whole body irradiation (900 cGy). With 
cytosine arabinoside protection, there was no need for bone marrow 
reconstitution of the animal (24, 30, 36). 
Congenitally athymic "nude" mice became available in the same period 
(26). Without further immunosuppressive treatment, these accepted grafts 
of some human tumors (11,12). Various strains of "nude" mice can now be 
obtained and the use of the athymic/asplenic ( Lasat) mouse (14,32) and the 
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athymic rat (10) was recently reported. 
Comparative studies on nude mice and immune suppressed mice condi-
tioned by thymectomy, cytosine arabinoside and total body irradiation have 
shown that the latter accept tumor grafts more readily (23). 
The choice between the "nude" and the artificially immunosuppressed 
animals is a difficult one at present (37). Artificially immunosuppressed 
animals restore the rejection mechanism at 4-6 weeks after the immunosup-
pressive treatment; they are not suitable for protracted experiments. The 
nude animals are about 3 to 4 times more expensive and require germ- free 
conditions. This complicates experimental manipulations, as breaches in 
aseptic environments have led to the loss of nude rat and mice colonies (37). 
A recent promising development is the six-day subrenal capsule assay. The 
host is a normal immunocompetent mouse. This assay seems to provide a 
relatively simple in vivo method for quick screening of the responsiveness of 
human tumor xenografts to chemotherapeutic agents (6). The method is 
suitable, however, only for fast growing tumors. 
There are four essential considerations in experiments using the in vivo 
models: 1) The end point chosen for therapeutic response, this can be 
growth delay, cell survival, inhibition of isotope incorporation or local 
tumor control. Tumor growth delay is the most common end point for the in 
situ response of xenografts. When a xenograft is treated in situ, the 
subsequent response will depend on both the effectiveness of the treatment 
and the host response to the tumor(20). There is evidence that host defense 
mechanisms are present in both "nude" mice and artificially immuno-
suppressed rodents (37); 
2) Variability of take rates of human xenografts. 
Adenocarcinoma, particularly of the colon, and melanomas have been 
successfully transplanted in "nude" as well as immunosuppressed animals 
(18, 37). Breast carcinomas and various sarcomas showed a low take rate 
(1). Natural selection for tumor cells which grow easily also tends to 
increase the take rate in the second or later passages. In contrast, the take 
rate of most human xenografts in second and later passages does not rapidly 
increase (18, 37); 
3) Maintenance of characteristics in xenografted tumors. The extent to 
which a human xenograft maintains the properties of the source tumor is an 
essential condition for the therapeutical prediction. Many authors state that 
the histological identity, chromosomal composition and tumor marker 
production and even the degree of differentiation of human xenografts are 
often well maintained (3, 10, 24, 33). The capacity of xenografts to 
metastatise is difficult to assess (25). Studies on the growth kinetics of 
xenograft tumors by the technique of labelled mitosis (31) have shown that 
cell proliferation in xenografts tends to be more rapid than would be 
expected on the basis ofthat of the source tumor, but the differences are not 
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as great as are those in volume doubling times (37); 
4) Therapeutic response of xenografts in the in vivo models. It seems to be 
generally accepted that xenografts maintain a therapeutic responsiveness 
that is in accord with clinical experience (2, 37). Carcinoma of the colon, 
which is largely unresponsive to chemotherapy in man, gives limited and 
transient responses as a xenograft (22). Bronchial carcinoma xenografts 
maintained a chemotherapeutic response that paralleled clinical experience 
(33). 
In vivo radiotherapy of a series of ovarian carcinoma xenografts suggests a 
possible positive correlation with the patient response (11). 
1.1.1 Conclusion on the applicability of the in vivo models. 
There is evidence that human xenografts do maintain a resemblance to the 
human source tumor in many aspects, including therapeutic sensitivity. 
Important complications in assessing xenograft response are the pharmaco-
dynamic problems when comparing drug treatment in man and rodents. 
Detailed comparison of patient and xenograft responses must be critically 
evaluated. The interaction between the xenograft and the host animal 
requires further investigation. Both immunosuppressed and "nude' animals 
are potentially capable of recognizing a xenograft as a foreign antigen. The 
possible activation of rejection mechanisms is a potential source of artifacts 
in therapeutic studies. 
1.2 IN VITRO ASSAY SYSTEMS FOR HUMAN TUMORS. 
With in vitro assay systems, the sensitivity of tumor cells derived from 
human tumor material to antineoplastic agents can be determined in various 
ways. 
1.2.1 Morphological assessment of cellular damage in monolayer or 
organ culture 
Fresh human tumor fragments are established as expiant cultures in chick 
embryo extract clots on cover slips and supplied with media supplemented 
with autologous or pooled human sera. When growth is established, the 
effects of antineoplastic drugs are evaluated by microscopic assessment of 
cell damage (17, 21, 40, 41). Although the primary results were encoura-
ging, the applicability of this method is limited due to the inability to 
standardize the cultures or to quantità te the results in order to determine the 
concentration and persistence of the cytotoxic agent in the tissues (21). 
Another limiting factor is that both malignant and nonmalignant cells grow 
in expiant cultures and overgrowth of fibroblasts can complicate the test in a 
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relatively short time (16). 
1.2.2. Inhibition of radioactive precursor incorporation. 
Slices of human tumors are incubated in the presence of radioactive tracers 
and cytostatic compounds. Drug effects are estimated from changes in the 
rate of incorporation of radioactive precursors of DNA, RNA and protein 
(5, 34). An accurate determination of cell survival may not be achieved by 
the precursor incorporation test This may be due to the lack of incorpora-
tion of DNA precursors by cells with a long cycle time. Precursor 
incorporation into cells may be temporarily halted because of damage to 
cells in the isolation process. Most drugs have profound effects on 
nucleotide synthesis. Decreased DNA synthesis may be due to drug-
induced depression of labeled nucleotide transport or changes in the 
nucleotide pool. Finally, the problem of incorporation of DNA precursors 
by a heterogeneous mixture of cells is a limiting factor (16). 
1.2.3 Clonogenic cell assay. 
This promising technique is being widely studied at present 
Single cell suspensions are exposed to a variety of chemotherapeutic agents, 
suspended in agar medium supplemented with horse serum and seeded in a 
petri dish containing conditioned medium. Colonies appear in 10 to 21 
days. The plates are examined for drug effects after about 14 days. The 
cloning efficiency of human tumors is low, ranging from 0.01% to a few 
percent (16, 28). The cells that do clone may not be representative of the 
total in vivo stem cell population (28). The evaluation of the test results by 
colony counting is extremely demanding and time consuming, but the 
employment of an automated counting apparatus could simplify the 
development of this procedure (16). Despite of the limitations of this 
technique, there is evidence that the in vitro sensitivity of human tumors 
correlates with the in vivo response (4, 27, 39). 
1.2.4 Inhibition of cellular respiration assay. 
Serial dilutions of potential antitumor agents are incubated in direct contact 
with freshly isolated Ehrlich ascites tumor cells in agar medium. The effect 
of the agent is determined by the decrease in dehydrogenase activity as a 
direct reflection of decreased respiration, with methylene blue as the 
indicator (7). The main problem is that the metabolism of both malignant 
and nonmalignant cells is assessed. This fact has prevented the widespread 
use of the technique (13). 
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7.2.5 Multicellular spheroid assay. 
Essentially, multicellular spheroids are produced by prevenjing cells from 
adhering to the substrate. This is achieved in a suspension culture or by a 
nonadherent coating on the tissue culture vessel. The cells are prevented 
from forming a monolayer and tend to aggregate. When the aggregates form, 
the cells begin division and produce a spheroid assembly of cells which are 
capable of autonomous growth (38). An obvious feature of the spheroid is 
the three-dimensional cell to cell contact Response is assessed as both 
growth delay and cell survival after drug exposure and is compared with the 
in vivo response in the patient and that of the xenograft The multicellular 
tumor spheroid represents an elegant in vitro model for the study of the 
effects of a range of agents on small tumor masses. Studies to compare the in 
vitro spheroid response to the in vivo tumor response are in progress (38). 
1.2.6 Conclusion on the applicability of the in vitro models. 
The application of in vitro assays of cells cultured from human tumors is 
hampered by factors such as the selection of subpopulations of cells, the 
growth of both malignant and nonmalignant cells, the relevance of the 
responses and quantifications of dose/response relations. 
Common to all in vitro assays is the lack of exact determination of the 
concentration and exposure time to the tested drug dosage that would reflect 
the in vivo situation. Also, in vitro tests do not take into account in vivo 
factors such as conversion and metabolism of the agents in the host (For 
reviews, see references 16, 19 and 28). 
1.3 COMBINED IN VITRO AND IN VIVO SYSTEM. 
This system is based on the colony forming assay of tumor cells using an 
agar diffusion chamber (15, 29, 35). Millipore diffusion chambers contai-
ning tumor cells in semisolid agar medium are implanted into the peritoneal 
cavity of preirradiated mice. After a period of incubation, the millipore filter 
of each chamber is removed and colonies are counted under a binocular 
microscope. Cell suspensions of tumors treated with cytotoxic drugs or 
irradiation can be essayed for response using this technique with clonogenic 
cell survival as the end point 
1.4 OBJECTIVES OF THE PRESENT INVESTIGATION. 
From the above review of the literature, it is obvious that various techniques 
and systems are available for growing human tumors or cells derived from 
tumors in vivo and in vitro. The main purposes of these systems are the 
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testing of the efficiency of cancer treatment modalities and studying human 
tumor biology and its interaction with the host mechanisms. None of the 
human tumor growth systems available so far fully satisfy these objectives. 
The aim of the work described in this thesis was to develop a new model for 
in vivo human tumor xenografts which would fulfil the following criteria: 
1 ) simplicity and reproducibility of the technique of preparation of the 
animals for experimentation; 
2) availibility of the animal supply at a reasonable cost; 
3) suitability of the animal for experimental manipulation with regards to 
size, durability and life span; 
4) a high rate of tumor xenograft take; 
5) suitability for protracted studies; 
6) versatility of the model for multipurpose applications. 
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CHAPTER 2 
THE IMMUNOSUPPRESSIVE REGIMEN 
FOR TUMOR XENOGRAFT IN THE RAT 
2.1 BASIC ASPECTS OF THE IMMUNE RESPONSE OF THE 
RAT. 
2.1.1 Introduction. 
Each animal species may differ in its immune response to specific antigens. 
In addition, housing facilities, methods of blood sampling and host factors 
such as age, sex and latent infections may complicate the interpretation of 
results obtained in immunological studies (14). The immune response of the 
rat to pathogenic agents and tumors is a result of complex interactions 
between antibodies, lymphocytes, macrophages and the antigens. Two 
classical forms of immune response can be distinguished: the humoral and 
the cell-mediated. The majority of these immune reactions are not an either-
or-all situation of antibodies versus cells; instead, they exhibit more mixed 
characteristics. Predominance of one type may change during the course of 
an immune reaction such as in the case of transplantation, particularly as a 
result of immunosuppressive therapy (42). 
2.1.2 Humoral immune response, specific antibodies. 
Antibodies are specialized proteins, immunoglobulins (Ig), formed by 
plasma cells in response to antigenic stimuli. They are capable of reacting 
specifically with the presented antigen. Five major classes of immuno-
globulins are found in the blood of the rat. There are immunoglobulin G 
(IgG), IgM, IgA, IgD and IgE (14). The wealth of knowledge presently 
available on rat immunoglobulins is mainly the result of studies on the LOU 
ileocecal malignant immunocytoma (2). The basic structure of immuno-
globulins is that of four peptide chains. Two of these are heavy (H) and the 
other two are light ( L) chains. They are connected by interchain disulphide 
bonds. Each chain has genetically determined constant and variable 
regions. The enzyme papain can split the immunoglobulin molecule into 
three fragments. Two of them are identical, univalent fragments which are 
capable of combining with antigens; they are called the Fab fragments 
(fragment antigen binding). The third fragment, Fc (fragment crystalliz-
able), is not capable of combining with antigen. Variations exist in the 
molecular structures of the five immunoglobulin classes. Each of them has a 
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distinct type of heavy chain. These H chains are called gamma, alpha, mu, 
delta and epsilon for the immunoglobulins IgG, IgA, IgM, IgD and IgE, 
respectively (14). Subclasses can be distinguished within the IgG class: 
IgGl, IgG2a, IgG2b and IgG2c (11). The physicochemical and 
biological properties of the five classes of immunoglobulins of the rat are 
summarized in Table 2.1. Specific humoral immune responses are 
mediated by antibodies produced by plasma cells and their precursors. In 
the primary response, IgM appears earlier and in a higher concentration 
than IgG. The latter occurs in much greater concentration after a second 
exposure to the same or closely related antigens (14). Antibodies in 
cooperation with macrophages, mast cells and serum factors (e.g., comple­
ment) are responsible for protective immunity, for instance, against 
microorganisms and other nonself antigens (14). It is generally accepted 
that the participation and cooperation of macrophages and lymphocytes are 
required, at least in response to most antigens (14). 
Table 2.1 Physicochemical and Biological Properties of Rat Immunoglobulin classes and 
subclasses (11, 19,63). 
Designation 
Heavy chains 
Light chains 
Sedimentation 
coefficient ( s) 
Molecular weight 
Half-life (d) 
Anubody activity 
- = no data 
IgM 
м 
к or λ 
18.2 
-
2.6 
+ 
IgA 
a 
к or λ 
7-19 
163 000 
+ 
+ = antibody activity present 
IgD 
S 
-
-
-
-
-
IgE 
с 
к or λ 
7.6 
183 000 
0 5 
+ 
IgGl 
ri 
к or λ 
6 7 
156 000 
-
+ 
IgG2a 
72a 
к or λ 
6 4 
156 000 
5.0 
+ 
IgG2b 
ΎΆ 
(cor λ 
6.5 
_ 
-
+ 
IgG2c 
y2c 
к or λ 
6.7 
156 000 
-
+ 
2.1.3 Cellular basis of immune responses. 
2.1.3.1 Lymphocytes. 
The presence of two populations of small lymphocytes in the thoracic lymph 
duct of the rat was demonstrated in 1958 by use of the tritiated thymidine 
labeling technique (7). In 1959, the recirculation of small lymphocytes 
traversing the postcapillary venules in the paracortex of lymph nodes was 
observed (29). In the spleen, recirculating lymphocytes enter the white pulp 
via postcapillary venules in the marginal zone. It is now generally accepted 
that hemopoietic precursor cells from bone marrow stem cells migrate to 
thymus and bursa equivalent organs (probably Peyer's patches and or the 
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appendix) where they proliferate and differentiate into the so-called Τ and В 
lymphocytes, respectively. Characteristics of the two types of immuno­
competent lymphocytes are presented in Table 2.2. The radiosensitivity of 
lymphocytes will be discussed in Section 2.3.2. 
Table 2 2 Characteristics of В and Τ lymphocytes of the rat 
Characteristics 
Recirculate from blood to lymph 
Thymus-specific alloantigen 
Fc en C3 receptors 
Surface immunoglobulin 
Localisation in lymph nodes 
Localisation in the spleen 
Susceptible to irradiation 
В cell 
+ 
-
+ 
+ 
follicles and 
medullary cords 
follicle peripheral 
regions of PALS 
+++ 
Τ cell 
+ 
+ 
-
± 
paracortex 
penartenolar 
sheath 
+ 
References 
29,38 
12 
64 
64 
14 
14 
14 
2.1.3.1.1 В Lymphocytes. 
Only 15-20% of the circulating lymphocytes are В cells. These are 
primarily responsible for the production of immunoglobulins. Their sur­
faces carry immunoglobulin molecules. After antigen contact, В cells 
transform into blast cells and differentiate into plasma cells which synthe­
size specific antibodies. Some of them become small long-living lympho­
cytes with a memory function of approximately 6 ± 2 months. В cells make 
up the main cellular compartment of the follicles and medullary cords in the 
lymph nodes and of the splenic lymph follicles and the outer periartenolar 
lymphatic sheath (PALS) of the spleen. 
2.1.3.1.2 Τ Lymphocytes. 
Τ lymphocytes develop and mature in the thymus under the influence of 
humoral factors or hormones (e.g., thymosin). They represent about 80-
85% of the circulating small lymphocytes and are long-living (probably 3 to 
6 months). Τ cells activated by antigens transform into blast cells and 
produce non-antigen-specific mediators (lymphokines, migration inhibition 
factor, chemostatic factor, cytotoxic factor by Τ killer cells, blastogenic 
factor). It is still a debatable question as to whether Τ cells of the rat also 
carry some surface immunoglobulins. A Τ cell specific marker, the 
alloantigen (Thy-1), has recently been determined. Rat Thy-1 is composed 
of several xenoantigenic determinants and appears to be a glycoprotein with 
a molecular weight of about25,000 (85). The distribution of Thy-1 antigen 
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in rats closely resembles that found in mice (21). 
An additional marker which is present on Τ cells as well as В cells has been 
termed the LC antigen (leucocyte common) (24). This antigen marker is 
identical to rat Ly-1(12). Factors produced by the various types of Τ helper 
and Τ suppressor cells are not yet clearly defined in the rat 
2.1.3.1.3 Monocytes and macrophages. 
It has still not been determined whether the mononuclear phagocytes of the 
rat which include monoblasts, promonocytes, monocytes and macrophages 
originate from the same stem cell. 
Indications are that 
a) blood borne monocytes are the source of immigrant macrophages (88); 
b) bone marrow precursors of rat monocytes have a cell cycle time of 18 
(87) tot 21 hours (92); 
c) the monocytes emerge from the bone marrow at a minimum of 6 to 8 
hours after the last precursor cell division (11). Macrophages are 
essential for the development of cellular and humoral immunocom-
petence (68). They contribute to at least four distinct but interlocking 
interactions in the host defense (Fig. 2.1) (68). 
delayed 
e f fector lymphokines .-.' h y p e r s e n s i t i v i t y 
F i g . 2 . 1 M a c r o p h a g e r e g u l a t i o n of i m m u n i t y ( 6 8 ) . 
( With the permission of the publ i sher) 
Fig. 2.1 Macrophage regulation of immunity (68). 
(With the permission of the publisher). 
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a) for the induction of T-lymphocyte proliferation, the physical presence of 
macrophages bearing antigens is required; 
b) the macrophage is the principal site of control by the immune response 
gene; 
c) macrophages have several plasma membrane receptors, such as those for 
the Fc portion of IgG, thus augmenting the cytotoxicity and phagocytosis 
of toxic agents during the secondary immune responses; 
d) macrophages secrete a wide variety of biologically active molecules 
(e.g., enzymes, complement components, enzyme inhibitors, binding 
proteins, nucleosides and metabolites, reactive metabolites of oxygen, 
bioactive lipids, chemotactic factor for neutrophiles, factors regulating 
the synthesis of proteins by other cells, factors promoting or inhibiting 
replication of other cells) (62). 
2.2 GENERAL ASPECTS OF ARTIFICIALLY INDUCED 
IMMUNOSUPPRESSION. 
Immunosuppression can be defined as the artificially induced state of 
naturally occurring anergy. 
Immunosuppressive therapy is meaningful only when the concerned 
immune reaction plays an essential role in the pathogenesis of the disease to 
be treated. The main clinical application of immunosuppressive therapy is 
the prevention or treatment of the rejection of transplanted organs and the 
treatment of autoimmune diseases and graft versus host reactions. 
The ideal immunosuppressive therapy should have a favourable therapeutic 
index, selective action on target immune responses and result in a state of 
unresponsiveness to the persistent antigen after withdrawal of the immuno-
suppressive agent (65). In general, immunosuppression can be divided into 
three etiological types (Table 2.3;89): natural immunological unresponsi-
veness, pathologically induced immunosuppression and artificially induced 
immunosuppression. 
Artificially induced immunosuppression can be classified into seven 
categories: 
a) desensitization to antigen; 
b) administration of specific immunosuppressive antisera or antibodies; 
c) use of antilymphocyte sera; 
d) immunosuppressive drugs and hormones; 
e) radiation; 
f) surgical removal of lymphoid tissue; 
g) plasmapheresis. 
In the following paragraphs, artificially induced immunosuppression will be 
discussed. 
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Table 2.3 Types of immunosuppression (89) 
Class Mechanism of induction 
Natural immunological unresponsiveness Induced tolerance to self-antigens during 
individual development 
Pathologically induced immunosuppression Immunodeficiency diseases resulting in en­
hanced tumor growth and an increased num­
ber of infections 
Artificially induced immunosuppression a) Antigen desensituation 
b) Use of specific antisera 
c) Excess of antigen-specific antibody 
d) Immunosuppressive drugs and hormones 
c) Radiation 
0 Surgery 
g) Plasmapheresis 
2.2.1 Antigen desensitization. 
The use of specific antigens as a method of inducing suppression, e.g., 
allergen desensitization, is well known. The induction of suppression 
largely depends on the molecular structure of the antigen and the route and 
time of its administration. 
2.2.2 Tolerance induction by antisera or specific antibodies. 
The immune system can "shut itself off' by a homeostatic feedback 
mechanism if a surplus of antibodies is present So, the injection of specific 
antibody against the challenging antigen will suppress the immune response 
to that antigen. Clinically, this technique is applied in the immediate 
postpartum period in Rh negative women potentially sensitized to 
Rh antigens during labor and parturition. This is to prevent the Rh positive 
fetus from developing erythroblastosis in a subsequent pregnancy. 
2.2.3 Antilymphocyte serum. 
The administration of specific antibodies against lymphocytes induces a 
nonspecific decrease in most primary immune responses. After the injection 
of antilymphocyte (antitheta) serum, the number of lymphocytes decreases 
(mainly Τ cells). The cell-mediated immune response is subsequently 
abolished. The effect on humoral responses is variable. Antilymphocyte 
serum is effective in suppressing cellular immunity in a variety of graft 
situations. When the administration of the agent is terminated, the immune 
response returns to normal. 
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2.2.4 Immunosuppressive drugs and hormones. 
A great number of drugs and hormones have the capacity to suppress the 
humoral and/or cellular responses to antigens to a varying extent Suppres­
sion depends on the degree of toxicity of the agent for В and T-lymphocyte 
subpopulations and hence also on their capacity to produce antibodies. 
Most drugs and hormones are effective during the induction phase of the 
immune response to an antigen but not during the effector phase. The 
primary response to an antigen is more easily inhibited than is the secondary 
response, probably because of terminal differentiation of most cells 
involved in the memory function. Furthermore, the effect of an immunosup­
pressive agent on the primary response is greatly dependent on the time of 
administration: prior, during or after antigen contact 
2.2.4.1 Immunosuppression by cytotoxic drugs 
The cytotoxic agents primarily developed for cancer treatment possess 
significant immunosuppressive activity because of their affecting immuno­
logically competent cells. The effects of these agents depend on the 
proliferative status of the target cell and the cell cycle specificity of the 
agent 
Although most cytotoxic compounds have immunosuppressive properties, 
cyclophosphamide and azathioprine are mainly used in clinical practice. 
Azathioprine, a phase-specific drug, is especially toxic during DNA 
synthesis. Cyclophosphamide, a cycle specific drug, exerts its lethal effect 
on cycling cells as well as on those in interphase. The use of these agents is 
limited by several and potentially serious side effects such as bone marrow 
depression, susceptibility to infections, gastrointestinal toxicity, infertility, 
hepatic dysfunctions, hemorrhagic cystitis, alopecia and probably an 
increased risk of malignancies. In addition to the well-known cytotoxic 
drugs, a new compound with immunosuppressive properties but without 
antitumor activity has been recently developed (4). This agent, cyclo­
sporin A, will be discussed in Section 2.3.3. 
2.2.4.2 Immunosuppression by hormones. 
Hormones, particularly corticosteroids, exhibit potent immunosuppressive 
activity. The exact mechanism is not precisely known. Steroids influence 
immune reactions in different ways. These include: 
a) the prevention of the migration of Τ cells to the site of the antigen; 
b) the prevention of the release of lymphokines essential for the recruitment 
of cells from lymphocytes; 
c) a reduction in the number of macrophages and monocytes; 
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d) the interference with the local interaction of lymphocytes and macro­
phages. 
The administration of a large dose of steroids results in a reduction in 
lymphocytes in the peripheral and central compartments. Both Τ and В cells 
are affected, although Τ lymphocytes are selectively influenced. 
2.2.5 Radiation. 
Most lymphocyte populations, their precursors and the stem cells in bone 
marrow are very radiosensitive. When survival curves are plotted, D 0 
values are in the range of 0.6-0.8 Gy, other cell lines originating from 
normal or tumor cells have D 0 values of about 1-1.5 Gy. 
There are four methods available for the immunosuppressive application of 
radiotherapy: 
a) local irradiation, applied, for instance, to reduce cell-mediated rejection 
of kidney allografts by abolishing of the lymphocytic infiltration; 
b) whole body irradiation as in preparation for bone marrow trans­
plantation; 
c) extracorporal irradiation of the circulating blood to reduce the mediators 
of the cell-mediated immune response (13, 90); 
d) total lymphoid irradiation, applied in experimental and clinical allograft 
transplantation and drug-resistant rheumatoid arthritis. 
The mechanism involved in the total lymphoid irradiation will be discussed 
in Section 2.3.2 of this chapter. 
2.2.6 Surgical removal of lymphoid tissue. 
Surgical removal of lymph nodes, the thymus or spleen can alter the immune 
response. Especially, removal of the thymus can result in a loss of the 
immunosurveillance components. 
In some autoimmune diseases, splenectomy is performed as an immuno­
suppressive treatment. 
Staging laparotomy with splenectomy in Hodgkin's disease is known to 
result in reduced immune responses. 
2.2.7 Plasmapheresis. 
The mechanism is based on a reduction in specific pathogenic antibodies 
and immune complexes. 
Clinical applications include the treatment of systemic lupus erythematosus 
and drug resistent rheumatoid arthritis. 
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2.3 INDUCTION OF IMMUNOSUPPRESSION BY CYCLOPHOS­
PHAMIDE, TOTAL LYMPHOID IRRADIATION AND CY­
CLOSPORIN A. 
For the induction of immunosuppression in animals in the model presented, 
cyclophosphamide, total lymphoid irradiation and cyclosporin A were 
applied. In the following sections, the major properties and mechanisms of 
these immunosuppressive agents are described. 
2.3.1. Cyclophosphamide. 
Pharmaceutical names of cyclophosphamide are Endoxan, Cytoxan, 
Procytox or Sendoxan. 
The chemical formula is C 7 H 1 5 C 1 2 N 2 0 2 P and the molecular weight is 261. 
The chemical name is 2- [Bis(2-chloroethyl) amino] tetrahydro-2H-l,3,2 
oxazaphosphorine 2-oxide. 
Its solubility in water is 40 g. Γ . It is slightly soluble in alcohol, benzene and 
ethylene glycol. 
The LD50 intraveneously in rats is 160 mg. kg. 
2.3.1.1 Metabolism of cyclophosphamide. 
-1 (59). 
Cyclophosphamide remains inactive until metabolized by the hepatic 
microsomal mixed function oxidases (70). A range of biologically active 
and inactive metabolites are subsequently formed (26,32). From data 
accumulated in recent years, the most likely pathways of cyclophos­
phamide metabolism are the formation of compounds I-V, Figure 2.2 (26, 
32, 57). 
A C T I V E M E T A B O L I T E S 
M I X E D 
F U N C T I O N 
O X I D A S E 
I 
OHC 
L I V E R 
A L D E H V D C 
O X I D A S E 
CAHBOXYPHOSPHAMIOE . 
J 4 - K E T O C Y C L O P H O S P H A M l O E 1 
I N A C T I V E M E T A B O L I T E S 
Fig, 2.2 Schematic representation of the metabolic pathway of cyclophosphamide. 
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The initial oxidative activation of cyclophosphamide (I) by microsomal 
mixed function oxidases in the liver occurs at site C4, the atom adjacent to 
the ring nitrogen, producing the cyclic 4-hydroxycyclophosphamide (II). 
This metabolite undergoes further oxidation to 4-ketocyclophosphamide or 
tautomerizes to the open-chain aldehyde aldophosphamide (III). The 
aldophosphamide may be oxidized to carboxyphosphamide or may undergo 
spontaneous beta elimination of acrolein (V) to form the phosphoramide 
mustard (IV). The major urinary metabolites are the carboxyphosphamide 
and 4-ketocyclophosphamide (82). 
It is generally accepted that the phosphoramide mustard is the active 
alkylating agent (16, 26). 
Acrolein is probably the compound which causes urothelial toxicity (17, 
18). 
The effect of cyclophosphamide metabolites on rapidly proliferating cells, 
e.g., lymphocytes, appears to be due to cross-linking of DNA strands 
resulting in lethal damage. Selective damage to В lymphocytes results in 
suppression of the humoral branch of the primary immune response. The 
pharmacology and metabolism of cyclophosphamide have been studied in a 
variety of species, including the mouse, the rat and man. The results indicate 
that the pharmacology and the metabolism of this agent are very similar in 
these species (26). 
However, certain differences, mainly concerning the enzymatic activation 
of the drug as metabolized by the hepatic microsomal enzymes, have been 
observed. 
Plasma concentrations of unchanged cyclophosphamide in rats, mice and in 
man were determined with specific mass spectrometric techniques (41,84). 
The mean plasma half-life of cyclophosphamide in the rat is longer than in 
the mouse (84) but shorter than in man ( 1.8-9.2 hours) (Table 2.4). 
Table 2.4 
Estimated half-life of unchanged cyclophosphamide in plasma. 
Species 
mouse 
rat 
man 
Dose 
(mg. kg"1) 
10 
100 
200 
10 
100 
200 
10 
20 
Lp. : intraperitoneally 
i.v. : intravenously 
Route of 
administration 
i-P· 
i-P-
Lp. 
Lp. 
i-P-
Lp. 
LV. 
Lv. 
Half-life 
(min) 
17 
26 
25 
43 
39 
60 
>180 
>180 
References 
81 
26 
26 
26 
26 
81 
26 
26 
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It has been demonstrated that the level of cyclosphosphamide activating 
enzymes is three times higher in the liver of male rats than in that of female 
rats (15). Cystitis due to cyclophosphamide metabolites occurs less often in 
female than in male rats (18). This side effect will be discussed in Chapter9. 
2.3.1.2. Immunological aspects of cyclophosphamide. 
The immunosuppressive action of cyclophosphamide has resulted in two 
useful clinical applications. The first is in the suppression of the immune 
response prior to organ transplantation (for example, bone marrow and 
kidney) and the second is in the treatment of autoimmune diseases (for 
example, rheumatoid arthritis and Wegener's granulomatosis). 
The capacity of a cytotoxic drug to decrease the number of immunologically 
reactive cells depends mainly on its relative cell specificity and the 
proliferative status of the target celL Cyclophosphamide is a cell cycle-
specific drug and affects both intermitotic and cycling cells, with selectivity 
for the actively proliferating В cells (26, 89). 
This alkylating agent, therefore, has a more sustained suppressive activity 
for the humoral than for the cell-mediated response (26, 33, 39). 
The selectivity of this drug for В cells appears to be correlated with a slower 
rate of recovery of these cells during periods of drug withdrawal (89). 
The immunosuppressive effects on the cell mediated responses are variable. 
Enhanced cellular immune responses may be due to drug toxicity for 
suppressor Τ lymphocytes (25, 89). 
In summary, cyclophosphamide is a powerful immunosuppressive agent 
The main immunological properties are depression of the primary and 
decrease in the secondary humoral immune responses, a decrease in 
delayed hypersensitivity reactions and, as a result of selective action on the 
В lymphocytes, a subsequent decrease in the serum IgG level 
2.3.2. Total lymphoid irradiation. 
2.3.2.1. Biological effectiveness of ionizing radiation. 
A large amount of clinical and experimental information on the biological 
effects of ionizing radiations has been accumulated during the last thirty 
years. This information has contributed to the understanding of the 
fundamental mechanisms of the effects of ionizing radiation on cells, tissues 
and organisms (22, 31 ). Most cells which are lethally damaged by ionizing 
radiation lose their capacity for sustained proliferation when attempting 
mitotic division. Some radiosensitive cells, however, die during the 
interphase without entering mitosis. The mechanism of the interphase death 
is not fully understood. Mitotic death is generally caused by translocations, 
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chromosomal breaks and other structural lesions in the DNA molecule. 
Certain radiation-induced lesions such as single-strand breaks and base 
damage are readily repaired. Double strand breaks are difficult to repair and 
are usually lethal to the cell. 
Lymphocytes are highly radiosensitive. Their dose-response curve essen­
tially has no shoulder and the slope is much steeper when compared with 
those of other mammalian cells dying during mitosis. In contrast, lympho­
cytes are much less radiosensitive during the induction phase in response to 
an antigen; the slope of their dose-response curve resembles that of cells 
dying a mitotic death. These lymphocytes are stimulated and are destined to 
proliferate and to differentiate into either effector or memory cells (45). 
2.3.2.2 Alterations in immune responses secondary to irradiation. 
Ionizing radiation produces changes in the number of lymphocytes and 
hence in their immune functions. Immune responses have been studied in 
patients treated with fractionated radiotherapy with localized or extended 
fields for carcinoma of the uterus, bladder or lung and for Hodgkin disease 
(37, 45, 72). These studies revealed the development of peripheral 
lymphocytopenia, a depression of the in vitro responsiveness to phyto-
hemagglutinin, the elimination of both the mixed leucocyte and the in vivo 
delayed hypersensitivity responses to dinitrochlorobenzene (27) and to 
intradermally injected bacterial and fungal antigens. 
Most studies have shown that the impaired immune functions do not recover 
completely within the first few years after treatment The degree of 
postirradiation immunosuppression and the rate of its recovery are depen­
dent on the region irradiated, the number of fractions employed and the total 
dose and dose rate (27, 45, 80). 
Τ and В lymphocytes respond differently to radiation treatment (53). The 
dye exclusion method reveals that В lymphocytes are more radiosensitive 
than Τ lymphocytes, but both the Τ and В lymphocytes represent 
heterogeneous populations with respect to their radiosensitivity. This was 
confirmed in studies on cultured human lymphoid cells by the growth 
extrapolation method (43). 
At Stanford University, experiments with BALB/c (H2 d/d) mice receiving 
total lymphoid irradiation (TLI) with 17 fractions of 200 cGy (total dose 
3400 cGy) showed changes in the number of Τ lymphocytes and immune 
functions similar to those observed in man (79, 81). 
The proliferative responses to phytohemagglutinin and concanavalin A 
were negated immediately after TLI. The mixed leucocyte reaction (MLR) 
of peripheral lymphocytes was also depressed. Long-term studies demon­
strated a persistent Τ lymphocytopenia and a compensatory В lympho­
cytosis, complete recovery of MLR reactivity, impaired responsiveness to 
Т Г 
PHA and enhanced responsiveness to Con A (79,81). TLI treated animals 
showed an initial profound suppression of the primary and secondary 
antibody responses to sheep red blood cells, which gradually recovered. 
Memory lymphocytes, however, were not eliminated after TLI (94). 
In other experiments, specific transplantation tolerance to allogeneic 
organs after TLI was demonstrated (Table 2.5). The exact mechanism 
underlying the state of tolerance induced by TLI remains largely unknown. 
According to Fuks and Slavin (27), there is evidence that generation of 
nonspecific as well as alloantigen-specific suppressor cells may be involved 
in the induction and maintenance of this specific transplantation tolerance 
following TLI. 
Table 2.5 Summary of data of prolonged tolerance to allogeneic organ transplants in 
different species induced by fractionated total lymphoid irradiation. 
Species Organ References 
mouse bone marrow 73,75, 81 
dog bone marrow, kidney 51,66,78,79 
rat skin, heart, bone marrow 3, 81 
baboon bone marrow 60 
human kidney 61 
In mice treated with TLI and made tolerant to bovine serum albumin, 
specific suppressor Τ lymphocytes were shown to be involved in the 
maintenance of tolerance to the heterologous proteins (76, 95). The 
presence of nonspecific suppressor cells immediately after TLI and of 
specific suppressor cells in established chimeras were demonstrated by 
blocking the in vitro mixed lymphocyte reactions using coculturing experi­
mental systems (74). These data suggest that specific and nonspecific 
suppressor mechanisms may play a role in the specific tolerance state and in 
the nonspecific immunosuppressive state following TLI (27, 79). 
A single dose of TLI combined with cyclophosphamide was successfully 
used in a clinical study on immunosuppression in preparation for a well-
matched allogeneic bone marrow transplant in the treatment of aplastic 
anemia (48). This immunosuppressive schedule was adapted in the 
experiments described in following chapters. 
In summary, total lymphoid irradiation as an immunosuppressive treatment 
for allogeneic organ transplantation is still regarded as an experimental 
procedure. 
More data will have to become available from well-designed studies before 
its routine clinical application can be justified. 
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2.3.3 Cyclosporin Α. 
2.3.3.1 Introduction. 
Cyclosporin A (CSA), a neutral cyclic endecapeptide, is obtained by 
different extraction procedures from the fungi Cylindrocarpon lucidum and 
Trichoderma polysporum (44). The molecule of CSA consists of eleven 
amino acids, seven of which are N-methylated, resulting in the extremely 
hydrophobic properties (Fig. 2.3). The molecular weight is 1203 (49, 93). 
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Fig. 2.3 Structure of Cyclosporin A illustrating its hydrophobic nature. The beta-
hydroxy unsaturated С 9 amino acid (top) is unique to this compound 
The molecule has a butterßy shape 
2.3.3.2 General aspects of immunosuppression by CSA. 
The immunosuppressive properties of CSA were recognized in 1972 (4) 
and later studies in experimental animal models revealed several significant 
features of this new compound Firstly, its effect was rapidly reversible both 
in vivo (5) and in vitro (93). Secondly, CSA has a good therapeutic index 
and has minor nonspecific effects on the lymphoid and myeloid systems (4, 
49). A major problem was its lack of solubility in aqueous media. 
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Preliminary data obtained in a recently developed radioimmunoassay for 
CSA suggest an absorption half-life of 1-3 hours after oral ingestion, with a 
biological half-life of 4-6 hours (46) in man. 
2.3.3.3 Effects on Τ lymphocytes. 
Several studies have indicated that CSA selectively inhibits T-cell respon­
ses to antigens and mitogens (4, 54,93). However, the reported data on the 
effects of CSA on different lymphocyte populations are still controversial 
(34, 56). It appears, for example, that CSA treatment of mice during 
priming with a T-dependent antigen inhibits the effector function of Τ helper 
cells but permits the normal priming of the Τ helper cell (52). 
2.3.3.4 Effects on В lymphocytes. 
Cyclosporin A does affect В lymphocytes in a highly selective manner (49, 
50). This was concluded from studies on the response of mice to various T-
independent antigens (TI). The antibody response to Ή-2 antigens (hapten 
conjugates of nonmitogenic polymers: Ficoll and dextran) in mice is 
exclusively sensitive to inhibition by CSA, while responses to TI-1 antigens 
(hapten conjugates of mitogenic materials: Escherichia coli lipopolysac-
charide) are resistant. The difference in susceptibility cannot be determined 
in vivo. 
2.3.3.5 Effects on organ transplants. 
Cyclosporin A has been used in a variety of transplant models: mouse, rat, 
dog, rabbit and monkey (Table 2.6). Impressive results have been obtained 
with renal allografts across the major histocompatibility barriers in rats and 
rabbits(23, 30, 35). In these systems, CSA was given during a period of 14-
28 days and led to renal graft acceptance for indefinite periods in most 
animals. The mechanism of this state of tolerance remains unclear. This 
effect does not occur in all species. In the dog, kidney grafts are rejected after 
the stoppage of CSA treatment (8). Skin grafts in mice and dogs are 
accepted only during the period of CSA administration (6, 20). In the dog, 
the rejection of the skin graft can be reversed by starting again with the CSA 
treatment 
However, fully allogeneic bone marrow grafts in rats are accepted 
indefinitely if the recipients are treated with CSA for a limited period after 
transplantation (86). Extensive clinical trials with CSA have shown a 
remarkable success mainly with kidney and to a less extent with pancreas 
and liver allografts (10). Most patients have been maintained on CSA 
alone, while others have received supplements of the traditional immuno-
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suppressants such as, e.g., azathioprine and prednisone. Encouraging 
results are obtained in allogeneic bone marrow transplantation in man(28). 
The incidence of graft-versus-host disease in patients receiving CSA was 
significantly lower than in those given methotrexate as the immunosuppres-
sive agent 
CSA is a potent immunosuppressive agent which is well tolerated. The few 
major side effects reported are nephrotoxicity, hepatotoxicity and the 
development of malignant lymphoma (9, 50, 71). 
Table 2 6 Summary of allogeneic organ transplantation m different species. Treatment with 
cyclosporin A induced a significant prolongation of survival of the transplanted 
organ. 
Species 
rat 
mouse 
dog 
rabbit 
monkey 
human 
Organ 
heart, bone marrow 
skin 
kidney, skin 
kidney 
heart, lung 
kidney, liver, 
bone marrow 
pancreas 
References 
40,91 
55 
1,36 
6 
67 
10,28,31 
58, 69, 77, 83 
2.3.3.6 Conclusioa 
The mechanism of action of CSA is still largely unknown, except that it 
prevents lymphocyte activation. CSA is neither lymphocytotoxic nor 
antimitotic. The hydrophobic CSA molecule has a high affinity for cell 
membrane lipids (44) and it may alter the membrane architecture. 
Cyclosporin A can be considered as the prototype of a new generation of 
immunosuppressive agents characterized by its specific action on defined 
lymphocytic functions. It may be used for analysing lymphocytic subpopu-
lations and studying the mechanisms of lymphocyte activatioa Possible 
long-term effects are yet to be assessed. 
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3.1 ABSTRACT 
The technical and dosimetric aspects of total lymphoid irradiation (TLI) in 
the Wistar rat were evaluated as part of a set-up to develop a new model for 
tumor xenotransplantation. Information obtained from anatomical dis-
sections, radionuclide imaging of the spleen, lymphography and chromo-
lymphography was used to standardize the localization of lymph nodes, 
thymus and spleen. A practical advantage was found in the simultaneous 
irradiation through two portals cut out in a lead plate. The two portals 
encompassed the lymphoid tissue above and below the diaphragm. A 
specially designed masonite phantom was used to determine the dose 
distribution in the simulated target volumes. Ionization chamber dosimetry, 
thermoluminescence dosimetry and film densitometry were used for 
determining exposure and absorbed dose. Irradiation was performed with 
250 kV X rays (HVL 3.1 mm Cu). 
The dose rate was regulated by adjusting the treatment distance. The dose 
inhomogeneity determined in the target volumes varied between 80-100%. 
The side scatter dose to nontarget tissues under the shielded area between 
the two portals ranged between 20-30%. The technique and dosimetry of 
total lymphoid irradiation in Wistar rats are now standardized and validated 
and make possible tumor xenotransplantation experiments. 
Keywords: Lymphoid organs, Localization, Total lymphoid irradiation, 
Dosimetry. 
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3.2 INTRODUCTION. 
There is experimental and clinical evidence that immunosuppression and, 
as a consequence, transplantation tolerance is induced after total lymphoid 
irradiation (TU) in mammals (1,2,7-11,13,14,15,17,18,19). Such tole­
rance can prolong the period of acceptance of bone marrow, skin, heart and 
other organ allografts in animals with different histocompatibility antigenic 
aspects (1,2,8,9,13,14,15,17,19). 
The technical and dosimetric aspects of TLI in the Wistar rat have been 
thoroughly evaluated and standardized in our Institute. This was part of a 
set-up to develop a new model for tumor xenotransplantation in Wistar rats 
based on TLI combined with cyclophosphamide treatment (6). 
The purpose of this chapter is to describe the technique and dosimetry of 
TLI for the induction of immunosuppression in the Wistar rat. 
3.3 METHODS AND MATERIALS. 
3.3.1 Experimental animals. 
Three-month-old male Wistar rats (200g ± 5%) of the outbred strain 
С i^WU were used. The animals were bred in the Central Animal 
Laboratory in Nijmegen and originated from the Institute of Laboratory 
Animals, TNO, Zeist, The Netherlands. A total of 28 animals was used: 5 
for anatomical dissections, 13 for spleen imaging, 5 for lymphography and 5 
for chromolymphography. 
3.3.2. General procedures. 
The localization of lymph nodes, thymus and spleen was based on 
anatomical dissections (3,4,5,12), radionuclide imaging of the spleen (16), 
lymphography and chromolymphography (20). 
The anatomical dissections were performed by using a dissection micro­
scope* (magnification 20-25 X). 
3.3.3 Radionuclide spleen localization. 
After six hours of fasting, the animals were anesthetized with sodium 
pentobarbital at 0.03 mg per g body weight administered intraperitoneal-
ly. Intraveneous injection of about 300 microcuries of 99mTc-Antimony 
Sulphide colloid in a volume of 0.3 ml was given in the dorsal penile veia 
* Zeiss 
Narcovet, Apharmo BV, Amhem, The Netherlands 
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At about 20 minutes after injection, spleen activity was recorded with a 
gamma "camera provided with a pin hole collimator. A 3 cm skin/colli-
mator distance was used. The outline of the spleen activity was marked on 
the skin with lead strips of 1 mm thickness (Fig. 3.1). A radiograph00 was 
taken with 25 kV X rays using film and a screen" (Fig. 3.2). The animal 
was immobilized in the supine position on a calibrated table during these 
procedures. 
Fig. 3.1 Spleen imaging of the Wistar rat; spleen activity outlined with lead strips. 
H: hepar 
S: spleen 
3.3.4. Lymphography. 
The localization and size of lymph nodes were determined by the following 
procedure. Under anesthesia, as described above, the contrast medium^ 
was injected intranodally into a prepared lumbar lymph node, applied by 
means of an automatic injector with a speed of 0.01 ml. min . After 45 
minutes, a series of X-ray pictures was taken. The lumbar, cystemal and 
intestinal lymph nodes were visualized. 
Dyna4/15, Picker 
Senographe 500 t, CGR, France 
Kodak, NMB 
MinR 
Lipiodol UF, Guerbet, Byk BV, Zwanenburg, The Netherlands 
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Fig. 3.2 Radiological localization of the spleen. 
3.3.5 Chromolymphography. 
A subcutaneous injection of 0.05 ml methylene blue solution* was given in 
the dorsal part of one of the back paws of anesthetized animals. The blue-
colored lymph vessel from the lower section of the leg was prepared after 1 Ο­
Ι 5 minutes by use a dissection microscope and subsequently injected with 
1-2 microliters contrast medium mixed with Sudan black (2 mg. m l ) 
using a Hamilton syringe*. The black-colored inguinal and abdominal 
lymph nodes could then be prepared and localized using the dissection 
microscope. 
3.3.6 Dosimetry. 
3.3.6.1 Radiation source. 
The irradiation was performed with a250 kV X ray unit00 with aThoraeus II 
added filter, the HVL was 3.1 mm Cu. The dose rate in air as determined 
* Patent Blue V, Guerbet, Byk BV, Zwanenburg, The Netherlands 
Lipiodol UF, Guerbet, Byk BV, Zwanenburg, The Netherlands 
Bonaduz AG, Bonaduz, Switzerland 
00
 Stabilipan, Siemens 
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with a Baldwin Farmer dosimeter was 38.0 cGy.min" , for a field size 
of 10 X 10 cm2 at 50 cm. The dosimeter was calibrated against a secondary 
standard NPL dosimeter . Treatment distance, dose rate and field size 
varied according to the experimental set-up and are detailed later in the 
results section. 
3.3.6.2 Construction of the phantom. 
A rat-shaped phantom composed of two identical pieces of masonite was 
used. The total thickness was 2.6 cm and the total weight 280g. The density 
of the masonite was 1.08 g.cm and the linear absorption coefficient 0.154 
cm (beam HVL: 3.1 mm Cu). One half of the rat phantom was provided 
with small grooves in two perpendicular directions for inserting LiF 
dosimeters (length, 6 mm; diameter, 1 mm) to determine relative midplane 
doses in the irradiation set-up(Fig. 3.3). The phantom was placed between 
two perspex plates (density: 1.18 g.cm ) of 2 and 4 mm thickness, 
respectively, as part of a fixation frame placed on a block of masonite (12 
cm thick) (Fig. 3.4). 
Fig. 3.3 Masonite rat phantom with LiF dosimeters. 
Nuclear Enterprises LTD, Beenham, England 
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portal I portal Д 
— Pb plate 
perspex plate 
Fig. 3.4 Diagrammatic representation of the phantom measurement set-up. 
3.3.6.3. Measurements. 
Determinations of the maximum dose in the center of a field and the dose 
distribution within the masonite rat phantom were performed with thermo­
luminescence dosimetry (TLD) and film exposure. Using the TLD 
system* a series of TLDs were repeatedly calibrated against a standard 
dose of y uSr radiation to check the reproducibility (±2% range). The TLDs 
used for the measurements were calibrated against a known dose of a 3.1 
mm Cu HVL radiation beam. Exposure of film showed an almost 
rectilinear response up to a dose of about 8 cGy, corresponding to a density 
of about 0.5. The same calibration factor was valid for the direct radiation 
beam as well as for a beam transmitted through a layer of 0.2 cm perspex + 
1.3 cm masonite (equivalentto midplane thickness) or0.2 cm perspex + 2.6 
cm masonite (equivalent to transmission thickness). Maximum film densi­
ties were determined with a densitometer" (aperture, 3 mm diameter) in 
optical units. Isodensity curves were drawn by use of an automatic scanning 
densitometer systemcc with an aperture of 2 mm diameter. 
+ 
TLD-10; Therados AB, Uppsala, Sweden 
Kodak X-Omat Verification 
SakuraPDA-81, Japan 
Scanditronix RFA-3, Taby. Sweden 
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3.4 RESULTS. 
3.4.1 Standardization of irradiation portals 
From the information obtained by anatomical dissections, radionuclide 
imaging of the spleen, lymphography and chromolymphography, the lymph 
nodes, spleen and thymus were localized in the supine positioned rat and the 
irradiation portals were determined (Fig.3.5). 
Two anterior portals made in a lead plate were used. Portal I encompassed 
lymph nodes above the diaphragm, including the thymus, while portal Π 
encompassed lymph nodes below the diaphragm, including the spleen. 
Figure 3.6 shows the dimensions of the two portals made in a 4 mm lead 
plate (14 X 30 cm2) serving as an auxilliary diaphragm. The borders of the 
two portals are separated by 3.2 cm. The area of portal I is about 18 cm2 and 
that of portal II about 35 cm2; the backscatter factors used for portals I and II 
are 1.12 and 1.16, respectively. 
The irradiation field for portal I measures 8 X 8 cm2, that of portal II is 10 X 
11 cm2; for portals I and II simultaneously, it is 11 X 20 cm2. 
Fig. 3.5 Representation of the standardized treatment portals encompassing the 
major lymphoid organs above and below the diaphragm. Lymph nodes 
are indicated by black dots. 
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3.4.2 Dosimetry. 
To achieve a maximum dose rate of 60.0 cGy.min'1 midplane, the focus 
phantom distances (f.p.d.) for portals I and II were 39.5 and 40.9 cm, 
respectively. The percentage depth doses at a depth of 1.5 cm tissue-
equivalent material were 88.0% and 91.2%, respectively, when either 
portal I or II was separately irradiated. Because of the shallow depth 
involved, the differences in density between water, masonite and perspex 
were negligible. For portal II, e.g., the dose on the central axis at d= 1.5 cm 
is composed of 82% of primary and 18% of scattered radiation. For 
simultaneous irradiation of both portals with a field size of 11 X 20 cm2, the 
f.p.d had to be increased to 71.0 cm to achieve a maximum dose rate of 20.0 
cGy.min midplane in portal II; the dose rate in the maximum of portal I 
was 5% lower. The entry point of the central axis was situated between 
portals I and II on the lead plate in the irradiation set-up (Fig. 3.6). 
Fig. 3.6 Portals I and II cut out in a lead plate. 
+ ; entry point of central axis. 
The midplane isodensity pattern (isodose pattern) after simultaneous 
irradiation of both portals with a maximum dose of 8 cGy in portal II is 
shown in Fig. 3.7. Dose inhomogeneity in the portal regions ranged from 
80% to about 100%. 
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In the shielded region between the two portals, a scatter dose ranging from 
20-30% of the maximum in portal II was determined. These values were in 
agreement with the TLD measurements. To compare the different depth 
doses in portals I and II, the rat phantom was replaced by 8 masonite plates 
(total thickness, 2.6 cm) of 6 X 20 cm2 (weight, 320 g). 
Films were inserted at 0, 6.5, 13, 19.5 and 26 mm depths. After 
simultaneous irradiation of portals I and II, the density maxima of each field 
on the exposed film were determined (Table 3.1). The densities in portal I 
were about 5% lower than those in portal II. Normalization of the two 
density series ( depth, 2 + 0 mm = 100%) gives the relative field depth dose. 
Fig. 3.7 Isodose lines of the absorbed dose distribution in the midplane, portals I 
and II treated simultaneously. 
d 
2 + 0 
2 + 6.5 
2 + 1 3 (midplane) 
2 + 19.5 
2 + 26 
Zmax'W 
0.41 
0.40 
0.39 
0.38 
0.37 
Z
maX^
ldI1 
0.43 
0.42 
0.41 
0.40 
0.39 
Percentage relative 
field depth dose 
(average) 
100 
98 
95 
93 
90 
Ζ -.maximum density measured onßlm in optical units 
d : depth (mm) 
Table 3.1. Relative field depth doses for portals I and II. 
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3.5 DISCUSSION. 
For studying the effects of TLI in experimental animals, the conditions of 
the experiments must be accurately defined. It is imperative to identify the 
target volume, to standardize the irradiation portals, to minimize nontarget 
tissue irradiation and to deliver the intended radiation dose as precisely as 
possible. Failing to define the target volume would in effect, convert a 
desired TLI set-up into an undesirable whole-body irradiation one. For 
these reasons, we made extensive efforts to define the topographical 
distribution of the major lymphoid tissues in our experimental animal. 
Our choice of the Wistar rat for these experiments was partly because of 
availability and partly for technical reasons. The rat has a more convenient 
volume than the mouse, lending itself to more reproducible and accurate 
irradiatioa It also has a larger blood volume for sampling and monitoring 
the immune response. 
In addition, its life expectancy is longer than two years, which suits the 
purpose of our experiments. 
The experiments performed to localize the lymphoid tissue in the Wistar rat 
demonstrated that the spleen has a variable anatomical position. This fact 
was taken into consideration in establishing the size of the standard 
irradiation portals. 
The dosimetry experiments confirmed the reproducibility of our set-up and 
irradiation factors. The inhomogeneity in the target volume was acceptable 
and varied between 80-100%. The dose to the nontarget tissues under the 
shielded area between the two irradiation portals ranged from 20-30%. This 
was because of the relatively high side-scatter dose of the beam used in this 
study. 
For the purpose of our experiments, this scatter dose was acceptable; 
however, if one is interested in reducing this dose further, a higher energy 
beam would be advisable. 
The simultaneous irradiation of two portals encompassing the lymphoid 
tissue above and below the diaphragm proved to be of practical advantage. 
At a dose rate of 20 cGy.min" , it was possible to deliver a total dose of 900 
cGy TLI in 45 minutes. Thus, the duration of the anesthesia of the animal 
was not unduly prolonged All of the animals in these experiments and in 
subsequent ones performed with respect to tumor xenotransplantation 
tolerated the treatment very well (6). With the technique and dosimetry 
standardized and validated, meaningful experiments are in progress. 
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CHAPTER 4 
HEMATOLOGIC AND IMMUNOLOGIC RESPONSE TO 
TREATMENT 
4.1 INTRODUCTION. 
In studying the effects of the immunosuppressive regimen, certain hemato­
logical and immunological parameters were monitored. The hemoglobin 
concentration, hematocrit and the number of leucocytes, erythrocytes, 
platelets, lymphocytes and monocytes were determined. Determinations of 
serum IgG levels, phytohemagglutinin (PHA) and concanavalin A ( Con A) 
responses of the peripheral lymphocytes and the percentage of peripheral В 
lymphocytes were also made. The methods and the results are described in 
this chapter and, where applicable, are compared with reported data ( 1,2,3, 
4, 5, 6, 7, 8.). 
4.2 GENERAL PROCEDURE. 
Blood samples were always taken at09.00 a.m. and by the same technician. 
The amount of blood required from the ether anesthetized animals was 
obtained by retro-orbital puncture with a heparinized capillary tube (cat no 
1603, Gelman-Hawksley Ltd, Lancing, Sussex, England). After shaking 
three drops of blood for three seconds in an EDTA (ethylene diamine tetra-
acetic acid) containing siliconized agglutination tube on a mixer (Cenco 
Instrumenten Mij N.V., Breda, The Netherlands), ten additional drops of 
retro-orbital puncture blood were added and the mixture again shaken for 
three seconds. 
4.2.1. Determination of hemoglobin concentration, hematocrit and the 
numbers of erythrocytes and leucocytes. 
With the Toa Auto Dilutor AD 220 (Toa Medical Electronics, Kobe, 
Japan), 0.02 ml blood was diluted with 10 ml Isoton II solution (azide-free 
stabilized electrolyte dilutant for counting and size determination of blood 
cells with a Coulter Counter, produced by Coulter Electronics GMBH, 
Krefeld, West Germany) inaplasticcontainer(BeakerDB-l for automatic 
blood cell counter produced by Toa Medical Electronics Ltd, Kobe, 
Japan). After two calibration runs with standardized blood, the determi­
nations were carried out with the Coulter Counter(Model S 5 S/N 00571, 
Coulter Electronics Ltd, Luton, Beds, England). 
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4.2.2. Determination of platelets. 
A heparinized capillary tube ( Vitrex Microhematokrit tubes, length 75 mm 
and internal diameter 0.564 mm, Modulohm VS, Herlev, Denmark) 
containing 0.001 ml blood was filled with platelet oil (Hoekloos BV, 
Amsterdam, The Netherlands) up to the calibration line on the capillary, 
closed with seal-ease (Clay Adams, Parsippany, N.J., U.S.A) and cen-
trifuged for 15 seconds in a microhematocrit centrifuge (Gelman-Hawksley 
Ltd, Lancing, Sussex, England). After cutting the capillary at the oil/blood 
separation line, platelet-rich plasma was pipetted into 10 ml dilution fluid 
(Cellkit 7 crystals and Cellkit 7 liquid. Toa Medical Electronics, Kobe, 
Japan, dissolved in two liters of double distilled water). The determinations 
were carried out in duplicate with a thrombocounter (Thrombocounter-C, 
Coulter Electronics, Harpender, England) and preceded by calibration 
runs. The count was calculated by means of the coincidence table for the 
Coulter Thrombocounter. 
4.2.3. Differential counting of peripheral leucocytes. 
A drop of blood was spread on a glass slide (76 X 26 mm, Menzel Gläser, 
West Germany) by means of a cover glass (18 X 18 mm, Menzel Gläser) 
and, after drying, stained according to the May-Griinwald-Giemsa method 
and differentiated by light microscopy at 1000 X (6,7). 
4.3 DETERMINATION OF SERUM IgG. 
The rat serum was obtained by centrifugation of 0.5 ml coagulated retro-
orbital puncture blood for five minutes. As antiserum, the anti-rat-IgG CFc 
fragment (code: SHARA/IgG Fc, Lotnr 6-778, Firma Nordic, Tilburg, 
The Netherlands) was diluted 60 times with 3.5% polyethylene glycol, 
6000 M, inO.l molarNa2HP04.2H20,0.1 molar KH2P04 and0.1 molar 
NaCl and filtered through a millipore filter (0.45 micrometer). For the 
standard, pooled serum of ten three-month-old Wistar rats was used in 
fractions of 0.3 ml and stored at -20° G The determinations were carried 
out with 1 ml of 60 times diluted antiserum and 50 μλ of 400-600 X diluted 
rat serum. For each sample, a blank determination was made. After two 
hours of incubation at room temperature, the developed turbidity of the 
antigen-antibody complex was quantified by means of a nephelometer 
(Laser Nephelometer, Firma Travenol Hyland, Nivelles, Belgium). The 
intensity of the light scattering is a measure for the concentration of IgG in 
the serum. The figures were expressed as percentages of those of the pooled 
serum. 
59 
4.4 DETERMINATION OF PHA AND CON A RESPONSES OF PERI­
PHERAL LYMPHOCYTES AND THE PERCENTAGE OF PERI­
PHERAL В LYMPHOCYTES. 
4.4.1 Isolation of lymphocytes. 
With some modifications, the method of Kruisbeek(3) was used Lympho­
cytes were separated from heparinized blood by dextran sedimentatioa 
The erythrocytes in the buffy coat were lysed by osmotic shock. After two 
washings with culture medium(RPMI 1640 supplemented with 15% fresh 
rat serum and 5 X 10 M 2-mercapto-ethanol), the cell suspension was 
adjustedto4X 10 celkmT formitogen stimulationand2 X 10 cells.mr 
for immunofluorescence experiments. 
4.4.2 Determination of PHA and Con A responses. 
For mitogen stimulation, the cells were dispensed into the wells of 
microtitre plates (2 X 10 5 cells/0.15ml/well). 
Phytohemagglutinin(PHA, Difco, Detroit, Michigan, U.S.A.) orconcana-
valinA(ConA, Sigma, St Louis, Missouri, U.S.A.) were added, both at a 
concentration ofSju&O. 15 ml. Cultures were incubated in triplicate a t37 0 C 
for three days in a humidified atmosphere of 95% air-5% CO2. After 48h, 
the cultures were labeled with 0.4 ju,Ci of Η-thymidine during 24 h. The 
cultures were then harvested with an automatic culture harvester and H-
thymidine incorporation determined by liquid scintillation counting. The 
proliferative response was expressed as counts per minute (Cpm) per 
culture. The stimulation index (SI) was calculated as Cpm/culture with 
mitogen divided by Cpm/culture without mitogen. 
4.4.3 Determination of the percentage of peripheral В lymphocytes. 
The cells were washed once at 4° С with phosphate-buffered saline (PBS) 
supplemented with 1% bovine serum albumin (BSA). After 30 min 
preincubation at 37° C, the cells were washed twice with PBS-BSA 
solution. One drop of the cell suspension was then mixed with one drop of 
fluorochrome-labeled rabbit antiserum (anti-rat-Ig conjugated with fluores­
cein isothiocyanate (FITC), supplied by Nordic Immunological Laborato­
ries, Tilburg, The Netherlands). Incubation was at 4° С for 30 min. After 
incubation, the cells were washed twice with the 1% BSA solution and 
placed on a slide with one drop of buffered glycerol. The slides were 
examined under a Zeiss Standard microscope equipped with a Ploem-type 
vertical illuminator, a high-pressure mercury lamp (HBO 50) and a suitable 
filter combination. The percentage of lymphocytes with a positive immuno­
fluorescence was used as a measure for the proportion of В lymphocytes. 
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4.5 RESULTS COMPARED WITH DATA FROM THE LITERATURE 
Mean normal hematological values of the Wistar rat compared with data 
from the literature. 
HB 
(mmol/1) 
HC 
(1/1) 
RBC 
(101 2/1) 
Platelets 
(109/1) 
Sex 
M 
M 
M 
M 
M 
F + M 
M 
M 
M 
M 
M 
M 
M 
M 
F + M 
M 
M 
M 
M 
M 
F + M 
M 
M 
M 
M 
F + M 
M 
Age in 
Weeks 
12 
16 
20 
16 
29 
a 
6 
18 
a 
12 
16 
20 
16 
29 
a 
a 
12 
16 
16 
29 
a 
a 
12 
16 
16 
a 
a 
Mean 
9 02 
9 41 
9 48 
9 8 
9 6 
9 67 
8 43 
1104 
9 05 
0 436 
0 450 
0 430 
0 498 
0 508 
0 46 
0 474 
6 32 
6 95 
7 8 
7 8 
7 2-9 6 
8 95 
1113 
1042 
1087 
1240 
340 
HB hemoglobin content 
HC hematocrit 
RBC erythrocytes 
a adults 
M male 
h female 
+ own data 
SD 
0 46 
0 34 
0 35 
0 58 
0 028 
0016 
0 022 
0015 
0 43 
0 67 
0 40 
114 
87 6 
55 5 
70 0 
SEM 
0 049 
0 070 
0 0 1 4 
0 08 
0 09 
0 003 
0 003 
0 009 
0 003 
0 004 
0 078 
0 17 
0 06 
0 08 
20 5 
22 6 
124 
Ν 
87 
23 
6 
25 
25 
160 
87 
23 
6 
25 
25 
160 
31 
15 
25 
25 
160 
31 
15 
20 
160 
Re 
+ 
+ 
+ 
8 
8 
1 
6 
6 
4 
+ 
+ 
+ 
8 
8 
1 
4 
+ 
+ 
8 
8 
1 
4 
+ 
+ 
2 
1 
4 
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WBC 
(10y/l) 
Lymphocytes 
(%) 
Neutrophils 
(%) 
Monocytes 
(%) 
Eosinophils 
(%) 
Sex 
M 
M 
M 
M 
M 
F + M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
WBC 
a 
F 
M 
+ 
Age m 
Weeks 
12 
16 
20 
16 
29 
a 
6 
18 
12 
16 
20 
16 
29 
12 
16 
20 
16 
29 
12 
16 
20 
16 
29 
12 
16 
20 
16 
29 
leucocytes 
adults 
Temale 
male 
own data 
Mean 
8 99 
890 
9 05 
176 
16 2 
9 92 
6 7 
7 3 
88 9 
89 5 
90 I 
82 0 
85 0 
8 8 
9 3 
8 6 
16 7 
136 
1 6 
0 7 
0 2 
0 16 
0 0 
0 7 
0 5 
1 1 
1 2 
1 3 
SD 
0 94 
106 
0 62 
0 96 
3 90 
3 87 
3 53 
2 82 
2 24 
3 52 
0 88 
0 69 
0 26 
0 634 
0 45 
1 37 
SEM 
0 100 
0 22 
0 25 
0 52 
0 47 
0418 
0 763 
1 44 
1 36 
1 37 
0 03 
0 47 
1 44 
1 27 
1 34 
0 095 
0 14 
0 105 
0 07 
0 068 
0 094 
0 559 
0 19 
0 27 
Ν 
87 
23 
6 
25 
25 
160 
87 
23 
6 
25 
25 
87 
23 
6 
25 
25 
87 
23 
6 
25 
25 
87 
23 
6 
25 
25 
Re 
+ 
+ 
+ 
8 
8 
4 
6 
6 
+ 
+ 
+ 
8 
8 
+ 
+ 
f 
8 
8 
+ 
+ 
+ 
8 
8 
+ 
+ 
+ 
8 
8 
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The mean values for the different estimations vary widely among the animal 
laboratories. The differences between the mean values are influenced, 
among others, by the method of blood sampling, the methods of estimation, 
time of blood sampling, composition of the food and possible latent 
infections. Adult values are reached at the age of four months. The mean 
values listed above were used as reference points for the studies on 
immunosuppression. For the immunological parameters, no comparison of 
the normal values with data from the literature was made. 
The methods for determination of lymphocyte mitogen responses and 
proportions of В lymphocytes in the peripheral blood were too varied to 
warrant a fruitful comparisoa 
The values for the experimental animals were always compared with those 
obtained from controls handled under identical conditions (Table 5.1). 
Serum IgG levels in the experimental animals were compared with those 
from a batch of pooled sera from controls (Fig. 5.4). 
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TUMOR XENOTRANSPLANTATION IN WISTAR RATS 
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5.1 ABSTRACT 
Three-month-old male Wistar rats were treated with cyclophosphamide 
(4 X10 mg.ke ) and total lymphoid irradiation (900 cGy, dose rate 
20 cGy.min ). The effect of immunosuppression was monitored by 
lymphocyte counts, serum IgG determinations, PHA and Con A responses, 
proportion of В cells and histopathological studies of the lymphoid organs. 
At eight days after treatment, the lymphocyte counts, IgG levels and PHA 
and Con A values were decreased. 
Mitotic activity started in the depleted В and Τ cell areas of the peripheral 
lymphatic organs two weeks after treatment There was a 94 percent graft 
take of the mouse C22LR osteosarcoma. The optimum time for tumor 
xenograft transplantation is 4 days after treatment The duration of growth 
was 11 days and this was followed by regression up to day 21. Further 
experiments are in progress in attempts to prolong the period of immuno­
suppression in the adapted host 
Keywords: Total lymphoid irradiation, Cyclophosphamide,Immunosup­
pression, Histophathology, Xenograft tumor. 
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5.2 INTRODUCTION. 
Several animal models for tumor xenotransplantation have been developed 
and described (1, 2, 3, 4, 5, 6). 
Basically, these models utilize either genetically immune deficient hosts 
(nude animals) or immune deprived ones (thymectomized, irradiated 
neonatal animals). More recently, experimental and clinical data have 
demonstrated the immunosuppressive effects of total lymphoid irradiation 
(TU) (7, 8, 9, 10, 11, 12). 
The pioneer work performed at Stanford University (13,7), has shown that 
TLI can induce transplantation tolerance. Such tolerance can prolong the 
period of acceptance of bone marrow, skin, heart and other organ allografts 
in animals which differ greatly in their histocompatibility antigenetic 
aspects (14, 15, 16, 17, 18). 
During the past 12 months, a new model for tumor xenotransplantation in 
rats based on TLI combined with cyclophosphamide was developed. 
In this chapter the immune modification experiments are described and the 
results of tumor xenografts in the immune deprived rats are given. 
5.3 METHODS AND MATERIALS. 
5.5.7 Experimental animals. 
Three-month-old male Wistar rats (200 g ± 5%) of the outbred strain 
Cpjj: WU were used. They were bred in the Central Animal Laboratory in 
Nymegen and originated from the Institute of Laboratory Animals, TNO, 
Zeist, The Netherlands. 
The rats were housed in a laminar flow cabinet with a day/night rhythm of 
12 hours and provided with food pellets (SRM-A, Hope Farms BV, 
Woerden, The Netherlands) and sterilized water ad libitum. Terramycin 
(Pfizer Ltd) in a dose of 5 mg was administered orally each day. 
5.3.2 Tumor xenografi. 
The C22LR mouse osteosarcoma was used for xenotransplantation. 
The tumor originated in 1958 in the right tibia of a female (C 57 BL/Rij 
X CBA/Rij) F J hybrid mouse and was induced by 1 microcurie of 
strontium-90 per gram body weight The tumor was maintained and 
provided by the Radiobiological Institute, Rijswijk, The Netherlands. In the 
donor animal, the tumor volume doubling time ranged from 1.8 to 2.6 days. 
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5.3.3 Irradiation techniques and dosimetry 
Accurate localisation of the lymphoid organs (lymph nodes, thymus and 
spleen) was based on anatomical dissection (19), lymphography and 
radionuclide scintigraphy (Fig. 5.1). The radiation dosimetry was perfor­
med by means of thermoluminescent dosimeters and film densitometry in a 
masonite phantom. The dose distribution and isodose lines are shown in 
Fig. 5.2. The irradiation was performed with a 250 kV X-ray unit 
(Stabilipan, Siemens), Thoraeus II added filter, HVL 3 mm Cu. 
Fig. 5 Λ Lymph nodes in the Wistar rat are indicated by black dots and the 
irradiation portals used for total lymphoid irradiation by the surround­
ing lines. A single field of 11 X 20 cm2 with lead cut-out for portals is 
used 
5.3.4 Treatment schedule 
After an adaptation period of seven days in the laminar flow cabinet, the 
animals received cyclophosphamide (CY) intraperitoneally at 10 mg per kg 
body weight per day for four days. The cyclophosphamide solution was 
freshly prepared by dissolving 100 mg in 5 ml of water for injections and 
70 ml of dextrose 5% in water. After a two-day interval, this was followed 
by total lymphoid irradiation consisting of a single dose of 900 cGy at a dose 
rate of 20 cGy.min . 
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Animals were anesthetized by injections of Narcovet(Apharmo, Arnhem, 
The Netherlands) at a dose of 0.03 mg per gram body weight Tumor 
fragments of the C22LR mouse osteosarcoma measuring 1.5 X 1.5 
X 1.5 mm3 were transplanted into subcutaneous tunnels in control and 
treated Wistar rats. Two dimensions of the tumor were determined daily by 
calliper measurement and the volume was calculated as for an ellipsoid. 
Fig. 5.2 Dose distribution and isodose lines for TLI. 
5.3.5 Assessment of responses. 
Blood samples were obtained by retro-orbital punctures at regular time 
intervals after TLI. The total lymphocyte count was determined from the 
total leucocyte and differential counts in duplicate. Serum IgG determi-
nations were performed immunonephelometrically using the Hyland Nephe-
lometer. Rabbit anti-IgG (Fc Specific, Nordic) was used as the antiserum. 
The IgG values were compared with the IgG levels of pooled serum often 
untreated rats. 
Isolation and mitogen stimulation of peripheral lymphocytes were perfor-
med according to the method of Kruisbeek (20) with slight modification. 
Phytohemagglutinin (PHA) and concanavalin A (Con A) were used as 
mitogens, both at a concentration of 5 micrograms per 0.15 ml culture 
medium. The lymphocyte cultures were incubated for 72 hours in a 
microtitre plate culture system. After a 24-hour pulse labelling period with 
3H-thymidine, the radioactivity of the cultures was determined by liquid 
scintillation counting. 
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The proliferative response was expressed as cpm/culture. The stimulation 
index (SI) was calculated as the ratio of the cpm/culture with mitogen and 
the cpm/culture without mitogea Surface immunoglobin bearing В lympho­
cytes were determined by immunofluorescence microscopy. Fluorescein 
isothiocyanate (FITC) labeled rabbit antirat Ig was used as the antiserum. 
At regular time intervals, several animals were sacrificed and the lymphoid 
organs dissected and fixed in Camoy solution. Histologic sections 
(4 /um) were stained by haematoxylin-azofloxin (Mayer), methyl green 
pyroxine (Unna-Pappenheim-Kees) and the Goldner-Jerusalem modifica­
tion or periodic acid Schiff. The data were analyzed by means of Student's 
two sample t-test 
5.4 RESULTS 
5.4.1 Immunosuppression in rats treated with cyclophosphamide and 
total lymphoid irradiation. 
Profound immune suppression was demonstrated in the animals treated 
with cyclophosphamide and TLI. The proliferative responses of the 
peripheral lymphocytes after in vitro stimulation with PHA and Con A 
showed a marked depression at 8 days after CY and TLI, which was 
followed by a return to normal values after 29 and 43 days, respectively 
(Table 5.1). 
Time after 
treatment 
PHA responses 
Con A responses 
Stimulation index (SI) 
8 days 
1 3 (nd) 
1 0 4 ( 1 1 8 6 ) 
6 4 ( 1 1 8 6 ) 
11 8(27 6) 
1 6 (nd) 
2 2 (nd) 
2 0 ( 1 7 9 ) 
2 3(17 9) 
0 8(678 0) 
29 days 
166 4(47 1 ) + 
97 7(171 3) 
64 8(47 2) 
25 3(nd) 
142 3(235 7) 
234 4(530.1) 
43 days 
246 6(130 1) 
80 7(130 1) 
408 6 (238 6) 
156 3(238 6) 
+ Value in parenthesis indicates SI of controls 
nd not done 
Table 5 1 The proliferative responses ofpenpheral lymphocytes after cyclophosphamide and 
TLI treatment of Wistar rats, expressed in SI. 
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The lymphocyte counts were significantly (p < 0.001) depressed as 
compared with the control group for up to 4 weeks after CY and TLI 
(Fig. 5.3). 
The IgG values also revealed significantly lower levels (p < 0.01) as 
compared with the control group at 8 days after treatment; there was a slow 
recovery approaching the control level at 3 weeks following treatment 
(Fig. 5.4). The proportions of peripheral В lymphocytes determined as 
surface Ig bearing lymphocytes by the immunofluorescence technique were 
not changed at 8,29 and 43 days after treatment The prominent histopatho-
logical changes during the first week after CY and TLI were as follows: 
a) collapse of germinal centers and shrinking of follicular structures in 
lymph nodes and spleen; 
b) accidental involution of the thymus; 
c) depletion of cortical areas of lymph nodes and splenic periarteriolar 
lymphatic sheaths. 
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Fig. 5.3 Lymphocyte counts as a function of time after CY and TLI treatment as 
compared with the control group. Bars indicate mean values and 
standard deviations. (8 animals per group). 
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Fig. 5.4 Serum IgG levels as function of time after С Y and ТЫ treatment as 
compared with the control group (8 animals per group). 
These different changes indicate deterioration of either the В and/or Τ 
lymphocyte compartments. During the second week, the early recovery of 
the immunocompetent system was manifested by the efflux of thymocytes 
via thymic lymphatics and the influx of lymphocytes through postcapillary 
venules in cortical areas in T-dependent areas and increased mitotic activity 
of centroblasts. Several mitoses, however, were abnormal, as indicated by 
clumped chromatin and metaphase arrest Complete morphological recon­
struction was not established before the 4th week. 
5.4.2 Tumor xenograft take and growth pattern 
At 0, 24, 48 and 96 hours after drug and irradiation treatment, tumor 
xenografts were transplanted in adapted hosts. The maximum tumor size 
was achieved with tumor fragments transplanted at 96 hours after treat­
ment, with a proliferation period of 11 days followed by tumor regression. 
No tumor mass could be detected at day 20 (Fig. 5.5). 
The rate of graft take of the xenograft tumor fragments was 94%. There was 
no tumor growth in the control group. 
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Fig. 5.5 Growth curves of the mouse osteosarcoma C22LR in the treated(CY+ 
TLI) Wistar rat as a function of time after tumor xenograft transplan­
tation: 0, 24, 48 or96 hours after treatment, respectively. Arrow indicates 
the time of xenograft transplantation Per group, 8-12 xenotransplants 
were used. 
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5.5 DISCUSSION. 
The continued search for an optimized animal model for human tumor 
xenotransplantation is of great interest to both the clinical oncologist and 
the experimental biologist A number of immune deficient rodent tumor test 
systems have been used for human tumor xenografting (1, 2, 3, 4). 
Basically, three classes of host systems are available: 
a) congenitally immune-deficient "nude" mice and rats; 
b) immune deprived thymectomized neonatal animals treated with anti-
lymphocyte serum and/or whole body irradiation; 
c) more recently, immune suppressed rodents using whole body irradiation 
and bone marrow reconstitution with or without protection with cytosine 
arabinoside (4, 5, 6). 
In a critical appraisal of human tumor xenografts. Steel and Peckham (21) 
found it difficult to choose between nude mice and immune suppressed 
mice. They argued that nude mice are approximately 3-4 times as expensive 
as immune suppressed mice and that germfree conditions are required for 
optimum survival. The choice of the immune suppressed Wistar rat model 
reported in this paper, using cyclophosphamide and TLI, has in our opinion, 
several advantages. Firstly, the rat is larger than the mouse and offers better 
accessibility to organs and tissues for experimental manipulation and a 
larger blood volume for convenient sampling. 
Secondly, using the combination of cyclophosphamide and TLI, efficient 
immunosuppression can be achieved with a minimum of toxicity. Thirdly, 
the reversibility of the immune tolerance to the xenograft makes the model 
suitable for studying graft-versus-host and host-versus-graft reactions. 
Finally, the technique for establishing immune suppressed rats is relatively 
simple and, once standardized, the availability of a steady supply is 
guaranteed. 
According to the results of the experiments reported here, the maximum 
immunosuppression with cyclophosphamide and TLI is reached at about 7 
days after treatment The optimum time for tumor implantation is after 4 
days. This suggests an earlier period of nonresponsiveness prior to the 
apparent immunosuppression as determined by the immune parameters. 
Morphological alterations in lymphatic organs secondary to TLI and 
cyclophosphamide probably start at the time of clinical nonresponsiveness 
(22). 
In contrast, recovery of immune reactivity is indicated by histodynamic 
changes such as the efflux of thymocytes via thymic lymphatics and the 
influx of lymphocytes through postcapillary venules before the total 
reconstruction of the microarchitecture of lymphatic organs. Recovery of 
the immune reactivity and the beginning of xenograft rejection occurs 
simultaneously at about 11 days after tumor implantation. It is possible to 
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delay the recovery by the use of an immune moderator such as Cyclo-
sporin A (Sandoz Ltd, Basel, Switzerland) (23, 24). 
In experiments to be reported elsewhere, the period of tumor xenograft 
growth could be prolonged with Cyclosporin A. 
In a pilot study, we also succeeded in growing and maintaining a human 
colon adenocarcinoma xenograft with a graft take rate of 70 percent 
In future experiments, we plan to use the recovery-delay technique with 
Cyclosporin A to study the mechanisms of initiation and modification of 
tumor xenograft rejection. 
Summary: A new model for tumor xenograft is developed in Wistar rats 
using cyclophosphamide and total lymphoid irradiation. 
Immunological and histopathological studies show that maxi-
mum immunosuppression is achieved at about 7 days after 
treatment The optimum time for tumor xenograft transplan-
tation in this model is 4 days after treatment 
Recovery of immune reactivity and beginning of xenograft 
rejection occur about 11 days after tumor implantation. Graft 
take of the tumor xenograft is 94%. 
Current pilot experiments show that it is possible to delay the 
recovery of the immune reactivity by the use of Cyclosporin A. 
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CHAPTER 6 
GROWTH PATTERN OF TUMOR XENOGRAFTS IN 
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RADIATION ONCOLOGY BIOLOGY PHYSICS 
6.1 ABSTRACT. 
Wistar rats treated with cyclophosphamide, total lymphoid irradiation 
(TLI) and/or cyclosporin A (CSA) develop a state of immune suppression 
permitting the growth of tumor xenografts. Experiments were carried out on 
this newly developed model to investigate the growth patterns of a mouse 
osteosarcoma and a human colon adenocarcinoma. The combination of 
cyclophosphamide and CSA permitted a limited period of growth of the 
mouse osteosarcoma with a tumor take rate of 66%. 
No takes were observed with the human adenocarcinoma 
The combination of cyclophosphamide and TLI resulted in a period of 
immunosuppression followed by recovery of the immune status. During the 
period of immunosuppression, tumor xenografts showed a 94% take rate. 
The most efficient immunosuppression was achieved by a combination of 
cyclophosphamide, TLI and CSA administered on alternate days. Wistar 
rats subjected to this treatment showed prolonged tolerance to mouse 
osteosarcoma and human adenocarcinoma xenografts. 
There was no alteration in the tumor doubling time or histological 
morphology of the xenografts in the adapted host as compared with those in 
the donor tumors. The tumor growth curve showed a pattern of initial growth 
and then a period of stagnation which was followed by a steady but slower 
growth phase. 
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The significance of the results and the advantages of the rat model described 
in this chapter for human tumor xeno-transplantation are discussed. 
Keywords : immunosuppression, total lymphoid irradiation, cyclo­
sporin A, cyclophosphamide, tumor xenograft, mouse osteo­
sarcoma С 22 LR, human adenocarcinoma, Wistar rat 
6.2 INTRODUCTION 
In vivo (5,6,22,25,27,29) and in vitro (9,26) systems for tumor culture are 
presently available for the study of tumor growth characteristics and for the 
testing of therapeutic modalities. Although in vitro cell and tissue culture 
systems are well established, these still do not represent the natural 
biological conditions of tumor growth. In vivo tumor transplantation 
systems, in contrast, permit the growth of tumor tissue in an environment 
with an intact blood supply and microcirculation as well as the intact 
stroma. Such conditions allow close simulation of the original tumor tissue 
metabolism, its cell proliferation characteristics and the tumor/host inter-
actioa 
Several animal models based on either genetically immunedeficient hosts 
(nude mice and rats; 5,25) or immune deprived hosts (thymectomized, 
irradiated neonatal animals; 22,27,29) have been employed for tumor 
xenotransplantation. 
Such systems are extensively used and with variable results(5,6,22,27,29, 
30). A critical appraisal of the different models available, however, 
indicated the need for better ones. Steel and Peckham stated that the choice 
between nude mice and immunosuppressed animals is a difficult one at the 
present time (30). 
We have succeeded in developing a new model for tumor xenotransplan­
tation which has certain advantages over other ones. The model is based on 
immune modification of the Wistar rat by means of treatment with 
cyclophosphamide followed by total lymphoid irradiation (TLI) and 
administration of an immune moderator, cyclosporin A (Sandoz, Basle, 
Switzerland) (2,34). 
This chapter presents the results of tumor xenograft experiments and the 
tumor growth patterns in the immune modified Wistar rats. 
6.3 METHODS AND MATERIALS. 
6.3.1 Experimental animals. 
Three-month-old male Wistar rats (200 g ± 5 %) of the outbred strain 
CLuiWU were used The rats were housed in a laminar flow cabinet and 
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provided with food pellets (SRM-A, Hope Farms BV, Woerden, The 
Netherlands) and sterilized water ad libitum. Terramycin (Pfizer Ltd.) in a 
dose of 5 mg. kg was administered orally each day. 
6.3.2 Tumor xenografts and transplantation techniques. 
The C22LR mouse osteosarcoma and human colon adenocarcinoma were 
used for xenotransplantatioa The mouse osteosarcoma originated in 1958 
in the right tibia ofafemale(C57 BL/RijX CBA/Rij) Fj hybrid mouse and 
was induced by 1 microcurie of strontium-90 per gram body weight (18). 
The human sigmoid colon adenocarcinoma was surgically removed from a 
male patient in 1978 and propagated in nude mice. The tumor used in our 
experiments was obtained from the 10th passage of the tumor line(personal 
communication, Mrs. T. Smink). 
The tumor volume doubling time of the mouse osteosarcoma С 22LR in the 
donor animal ranged from 1.8 to 2.6 days and that of the human 
adenocarcinoma in the nude mouse ranged from 4 to 4.5 days. Tumor 
fragments of the С 22LR tumor and human adenocarcinoma measuring 1.0 
to 3.4 mm3 were transplanted subcutaneously into control and treated 
Wistar rats. 
6.3.3 Irradiation techniques and dosimetry. 
Accurate localisation of the lymphoid organs of the Wistar rat was based on 
anatomical dissection, lymphography and radionuclide scintigraphy (11). 
A detailed description of the irradiation technique is given elsewhere (11) 
(Fig. 6.1). 
The radiation dosimetry was performed by means of thermoluminescent 
dosimeters and film densitometry in a masonite phantom (11). The 
irradiation was performed with a 250 kV X-ray unit ( Stabilipan, Siemens), 
Thoraeus II added filter, HVL 3 mmCu. 
6.3.4 Treatment schedule. 
Cyclophosphamide was administered i.p. at doses of 10 mg.kg on four 
consecutive days. Total lymphoid irradiation was performed at a dose rate 
of 20 cGy.min . The dose administered was 900 cGy. Cyclosporin A 
(Sandoz, Basle, Switzerland) in Miglyol 812 (Dynamit Nobel AG, West 
Germany) was administered, according to the instruction of Dr. JF Borei 
( Sandoz), subcutaneously in the upper neck triangle at doses of 15,20 or 30 
mg. kg" on alternate days with correction of dosage according the increased 
body weight of the host animal. The animals were divided into six groups. 
The treatment schedule for each group is given in Table 6.1. 
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Fig. 6.1 Lead cut-out showing the irradiation ßeIds for TLI. 
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Time (day) 
Day 0 : rats placed in laminar flow cabinet 
Day 1-7 : adaptation period for schedules D.E and F 
Day 1-13 : adaptation period for schedule В 
Day 1-17 : adaptation period for schedules A and С 
CY: administration of cyclophosphamide intraperitoneally (10 mg.kg' ) 
TLI : total lymphoid irradiation (D.
 t .=900 cGy midplane; "d=20 cGy.min" ) 
TX : tumor xenotransplantation 
CSA : administration of Cyclosporin A subcutaneously on alternate days during the 
experiment (15, 20 or 30 mg.kg" ; see text) 
Table 6.1 Treatment schedules A-F 
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6.3.5 Assesment of responses. 
The effect of immunosuppression was monitored as outlined in a previous 
report (12). Blood samples were obtained by retro-orbital punctures at 
regular time intervals. The total lymphocyte count was determined from 
duplicate total leucocyte and differential counts. Serum IgG determinations 
were performed immunonephelometrically. Rabbit antirat IgG ( Fc specific, 
Nordic) was used as the antiserum. Lymphocyte stimulation tests were 
performed on isolated lymphocytes with phytohemagglutinin ( PHA) and 
concanavalin A (Con A) as mitogens (4,17). Excision biopsies of the 
tumor were taken at 24 and 36 days following tumor transplantation. 
Two dimensions of the tumor were determined daily for the osteosarcoma 
and weekly for the adenocarcinoma by calliper measurements. The volume 
was approximated by the formula Vtumor—-r-a-b. (a=greatest diameter). 
No correction for skin thickness was made. 
6.4 RESULTS 
6.4.1 Mouse osteosarcoma C22 LR 
I Control (treatment schedule A) 
Ten tumor fragments transplanted subcutaneously into five untreated 
rats showed no take. 
II Total lymphoid irradiation (treatment schedule B) 
Tumor fragments were transplanted within twenty-four hours after 
irradiation. All ten tumor grafts in five animals were not accepted 
Seven days after TLI, PHA and Con A stimulation of the peripheral 
lymphocytes showed the same levels as those in control animals. At 
that time, the lymphocyte count was maximally depressed. The serum 
IgG level was in the normal range. 
III Cyclosporin A at 20 mg.kg subcutaneously on alternate days 
(treatment schedule C) 
Twelve tumor fragments were transplanted into five rats. The CSA 
administration was started within twenty-four hours after transplan-
tatioa Four transplants in three animals showed limited growth (Fig. 
6.2). After an overall time of 13 days of CSA administration, the 
values for PHA and Con A stimulation of the peripheral lymphocytes 
were in the normal range, as were the number of lymphocytes and the 
serum IgG level. 
IV Cyclophosphamide and Cyclosporin A at 20 mg.kg subcuta-
neously on alternate days (treatment schedule D) 
Twelve tumor fragments were transplanted into five rats. Four were 
not accepted, while eight tumor grafts had a 16-day proliferation 
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Fig. 6.2 Four tumor growth curves showing a limited growth phase up to day 15, 
followed by rapid regression. Arrow indicates the time of transplantation. 
phase (Fig. 6.3), followed by regression. The tumor take rate was 
66%. 
Cyclophosphamide and total lymphoid irradiation (treatment sche­
dule E) 
Twelve tumor fragments were transplanted into six pretreated rats. 
All grafts increased in tumor volume for about 11 days. This was 
followed by regression (Fig. 6.4). Seven days after pretreatment, the 
values for PHA and Con A stimulation of the peripheral lymphocytes, 
the number of lymphocytes and the serum IgG level were all 
decreased ( 12). During the period of immunosuppression, the tumor 
xenografts had a take rate of 94% and increased in volume with a 
tumor volume doubling time ranging from 1.6 to 2.4 days. 
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Fig. 6.3 Growth curves of four tumor transplants. A proliferative phase up to day 
16, followed by regression lasting until day 24-31. The animals received 
Cyclosporin A on alternate days throughout Arrow indicates the time of 
transplantation. 
VI Cyclophosphamide, total lymphoid irradiation and Cyclosporin A at 
15 mg.kg subcutaneously on alternate days (treatment schedule F) 
(Fig. 6.5) 
All twelve transplants in five treated rats were accepted Eight tumors 
increased in volume up to day 15-16, followed by a regression of the 
tumor volume up to day 24-29. Four tumors showed a period of rapid 
proliferation with a tumor volume doubling time ranging from 1.6 to 
2.4 days. After a period of stagnation, a period of slower growth was 
observed. At days 47 and 48, the animals had to be killed because of 
the tumor load. 
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Fig. 6.4 Growth curves of four tumor transplants. A proliferative phase up to day 
13-14, followed by rapid regression of all tumor transplants. Arrow 
indicates the time of transplantation. 
VII Cyclophosphamide, total lymphoid irradiation and Cyclosporin A at 
20 mg.kg" subcutaneously on alternate days (treatment schedule F) 
(Fig. 6.6) 
All twelve transplants in five animals were accepted and showed a 
rapid proliferation phase up to day 16. The tumor volume doubling 
time ranged from 1.5 to 2.4 days. After a period of stagnation lasting 
until day 29, a period of growth for up to day 5 3-5 5 was observed (Fig. 
6.7). The animals then had to be killed because of the tumor load At 
day 54, the peripheral lymphocytes could not be stimulated by PHA 
and Con A. The ulceration of the tumor resulted in a leucocytosis with 
a shift to the left in the differential count 
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Fig. 6.5 Growth curves of four tumor transplants. After a proliferation phase, 
three tumors regressed and one grew, after a period of stagnation, for up 
to day 48. Arrow indicates the time of transplantation. 
6.4.2 Human colon adenocarcinoma 
II 
Control (treatment schedule A) 
Eight tumor fragments transplanted in four untreated rats were not 
accepted. 
Cyclosporin A at 30 mg. kg subcutaneously on alternate days 
(treatment schedule C) 
All ten tumor fragments transplanted in five animals were not 
accepted. After 18 days of CSA administration, the PHA and Con A 
stimulation of the peripheral lymphocytes and the serum IgG 
concentration were at the same levels as in the control group. 
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Fig. 6.6 Growth curves of four tumor transplants demonstrating a biphasic 
pattern. A rapid proliferation phase followed by a period of stagnation, 
then a slower growth phase until death at day 53-54. Arrow indicates the 
lime of transplantation 
III Cyclophosphamide and Cyclosporin A at 30 mg.kg" subcutaneously 
on alternate days (treatment schedule D) 
All eight tumor fragments transplanted in four animals were not 
accepted. After 18 days of CSA administration, the number of 
lymphocytes showed some depression but the serum IgG level was 
normal. 
IV Cyclophosphamide, total lymphoid irradiation and Cyclosporin A 
20 mg.kg" subcutaneously on alternate days (treatment schedule F) 
Of six transplants in three animals, two tumor fragments were 
accepted and grew until day 58-60. The take rate was 33%. After 18 
days of CSA administration, the number of lymphocytes showed a 
limited depression; the serum IgG level was normal. 
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Fig. 6.7 Mouse osteosarcoma (C22LR) after 55 days of proliferation in the 
adapted rat. 
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Fig. 6.8 Growth curves of three tumor transplants. A period of growth up to day 
60-70, followed by a period of regression lasting until day 98-112. There 
was no adjustment of CSA dosage to the increased body weight of the host 
animal after day 50. Arrow indicates the time of tumor transplantation. 
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V Cyclophosphamide, total lymphoid irradiation and Cyclosporin A at 
30 mg.kg subcutaneously on alternate days, (treatment schedule F) 
Because of limited supply of tumor material, only eight tumor 
fragments were transplanted into six adapted animals. Five trans­
plants were accepted and showed a proliferation phase up to day 60-
70 followed by regression lasting until day 98-112; the tumor take rate 
was 64%. (Fig. 6.8). After an overall time of 50 days of CSA 
administration, there was no correction of the CSA dosage for the 
increased body weight of the host animals. After 18 days of treatment, 
the PHA and Con A stimulation of the peripheral lymphocytes was 
depressed. The number of lymphocytes was decreased and the serum 
IgG level was in the normal range. 
6.4.3 Histology of the mouse osteosarcoma C22LR and the human 
adenocarcinoma in the adapted rat. 
6.4.3.1 Pretransplantation appearance. 
A Mouse osteosarcoma C22LR 
During repeated passages in syngeneic donor animals, the original 
pattern of the osteosarcoma changed morphologically to a poorly 
differentiated fibrosarcoma consisting mainly of anaplastic cells with 
marked variation in size and shape. The overall mitotic activity was high, 
ranging between 2.0 and 4.5 percent 
В Human colon adenocarcinoma 
In the human adenocarcinoma propagated in nude mice, small and large 
clusters and cords of epithelial cells forming the pattern of a carcinoma 
simplex were observed. Some pleomorphism was evident, as demon­
strated by variations in cellular and nuclear sizes. The number of mitotic 
figures was up to eight percent The growth of the tumor was expansive 
rather than infiltrative. 
6.4.3.2 Posttransplantation growth phase 
A Mouse osteosarcoma C22LR (Fig. 6.9a) 
The fibrosarcomatous appearance of the tumor and the percentage of 
mitotic figures were maintained, but the cells appeared more uniform in 
size. The tumor was not infiltrated by immunocompetent host cells. 
В Human colon adenocarcinoma (Fig. 6.9b) 
The tumor exhibited essentially the same features as described for the 
initial pretransplantation specimen. The number of mitotic figures 
remained high. 
Cords of tumor cells tended to infiltrate the striated muscle layer of the 
abdominal wall of the adapted host Host defense reactions against the 
tumor tissue were notably absent 
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Fig. 6.9а Mouse "osteosarcoma" C22LR at 24 days after tumor xenotrans­
plantation (treatment schedule F). Poorly differentiated fibrosar­
coma with a high mitotic rate (methyl green-pyronin stain 290 X). 
Fig. 6.9b Human adenocarcinoma at 36 days after tumor xenotransplantation 
(treatment schedule F). Large cords of tumor cells of solid appearance 
are characteristic of peripheral growth. Note tendency to infiltrate 
striated muscle layer of abdominal wall and the high number of 
mitotic figures (methyl green-pyronin stain 290 X). 
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6.5 DISCUSSION 
The results of the experiments described in this chapter demonstrate that 
treatment schedules D,E and F induce a state of immunosuppresion in the 
Wistar rat which permits the growth of tumor xenografts to a greater or 
lesser extent 
These treatment schedules consisted of cyclophosphamide and cyclo-
sporin A(CSA), cyclophosphamide and TLI and cyclophosphamide, TLI 
and CSA, respectively. 
As reported by several authors (1,8,14,16,20,21,23,28,31,32),TLI can 
induce transplantation tolerance. Kim et al ( 15 ) reported on the use of single 
dose TLI combined with cyclophosphamide as an immunosuppressive 
regimen for human bone marrow transplantation in patients with aplastic 
anemia. This prompted us to try the combination of cyclophosphamide and 
TLI for the immune adaptation of the Wistar rat However, our experiments 
showed that this combination produced a reversible immunosuppression. 
To modify the immune recovery, we used CSA as a moderator. Cyclo-
sporin A, a cyclic endecapeptide extracted from two species of fungi, is 
known to have in vivo (2) and in vitro (34) immunosuppressive effects. In 
organ transplantation experiments in the mouse (19), rabbit (7), dog (10), 
monkey (24) and man (3, 33), CSA was found to be effective in preventing 
acute allograft rejectioa Its effect was found to be reversible (2,34) and not 
cummulative. 
The most efficient immunosuppression was achieved in our system by the 
treatment according to schedule F, combining cyclophosphamide, TLI and 
CSA in a dosage of at least 20 mg. kg on alternate days. 
After an overall time of 18 days of CSA administration, in vitro stimulation 
of the peripheral lymphocytes was severely depressed. The serum IgG 
levels were in the normal range. Wistar rats modified by this treatment 
showed prolonged xenograft tolerance to mouse osteosarcoma C22LR and 
a human colon adenocarcinoma. 
There were no alterations in the tumor doubling time or histological 
morphology after transplantation of the osteosarcoma and adenocarcinoma 
in the modified host Immunocompetent cells, macrophages and plasma 
cells were absent in sections of the tumor graft. These cells are characteri-
stically involved in both cellular cytotoxicity and humoral mediated 
rejection (13). 
This clearly indicates a state of complete immune unresponsiveness at the 
time when the biopsy was takea The tumor take rate for the mouse 
osteosarcoma C22LR was 94% and for the human adenocarcinoma 64%. 
Of interest is the pattern of the tumor growth(Fig. 6.5 andò.6) with a period 
of no growth interspersed. 
This phenomen remains unexplained and requires further study. 
90 
Fig. 6.10 Human adenocarcinoma after 70 days proliferation in the adapted 
rat. 
The new model of tumor xenograft in the adapted rat as described in this 
chapter offers several advantages. 
As an experimental animal, the Wistar rat is of convenient size and with 
adequate accessibility to organs and tissues for experimental manipulation 
and suitable blood volume for sampling and subsequent monitoring of 
immune parameters. It is also readily available at relatively low costs. 
Furthermore, the combination of cyclophosphamide and TLI induces 
efficient initial immunosuppression with minimum toxicity. 
The reversibility of the induced immune tolerance can be moderated by 
prolonged administration of Cyclosporin A in adequate dosages (Fig. 
6.10). 
In later experiments, the Cyclosporin A dosage was adjusted according to 
the increase in body weight of the rat By increasing the dosage and the 
length of treatment with CSA it is possible to prolong the period of tumor 
growth and to study tumor-versus-host and host-versus-tumor reactions. In 
these experiments, it was possible to maintain the growth of human 
adenocarcinoma for up to 103 days. 
The fact that tumor growth in the adapted rat was promoted and prolonged 
during the administration of CSA suggests that CSA has no antineoplastic 
effect This aspect is important if the adapted rat is used for testing tumor 
sensitivity to cancer therapy. 
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The results of our experiments indicate the possible suitability of this rat 
model for human tumor xenotransplantatioa Further refinements of the 
technique are under way to optimize the dose, duration and route of 
administration of CSA in experiments with other human tumors. 
In summary, a new model for tumor xenotransplantation in the adapted rat 
is developed. 
The model is relatively simple to establish and, once standardized, the 
availability of a steady supply is guaranteed. 
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CHAPTER 7 
HISTOLOGY OF THE LYMPHOID ORGANS 
AFTER IMMUNOSUPPRESSIVE TREATMENT 
7.1 INTRODUCTION 
Glick (5) showed that the bursa of Fabricius was essential for full 
immunological competence in chickens (5) and Archer and Pierce (1) and 
Miller (13) had indicated that the thymus is essential for the development of 
certain immune reactions in animals. A large body of information had been 
accumulated on the different functions of these two lymphoepithelial 
organs. Although much controversy surrounds the question of whether 
there is an anatomic equivalent of the bursa in mammals, further studies 
have succeeded in identifying thymus-dependent (T) and bursa- or bone 
marrow dependent (B) areas in the peripheral lymphatic organs (16, 17) in 
mammals. At present, major attention is focused on factors involved in the 
regulation of the production and differentiation of В lymphocytes in the 
bone marrow (3). 
Further studies confirmed the observations of Gowans and Knight (6) that 
the peripheral immunocompetent lymphoid system consists of two com­
partments: the organ-bound one (lymph nodes, spleen, gut associated 
lymphatic tissue) and the compartment of circulating and recirculating 
cells. 
Lymphocytes of both the T- and B-cell lineages not only leave the lymphatic 
organs but they al so return to their " homing' ' areas whether sensitized or not 
(for a review see De Sousa, 4). 
The function of this recirculation is to transfer immunological information 
(afferent branch of the immune surveillance) to the periphery and, upon 
returning to the draining lymphatic organs, to transform the information into 
an adequate immune response (effector phase, efferent branch of the 
immune response of either the humoral, cell-mediated or the mixed type). 
Results of experiments performed to determine the role of the thymus in 
immune reactions revealed that the Τ and В lymphocytes do not home 
arbitrarily in the lymphoid organs but prefer particular topographic regions 
(19). 
For Τ cells, these are the inner cortex (paracortical area) in the lymph 
nodes, the periarteriolar sheath in the spleen and the interfollicular area in 
the gutassociated lymphatic tissues. The В cells represent the major 
population in the lymphatic follicle structures. 
Natural or experimentally induced changes in the distribution of Τ and В 
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cells over the homing compartments and/or the recirculating compartment 
may result in alterations in the immune response. 
Since in the present study the immunosuppressive treatments mainly 
affected the organ-bound compartment of the immune system (see Chapter 
2), an attempt was made to correlate the morphological changes observed 
with the capacity of the animals to accept or reject the xenogeneic tumor. 
It is, however, beyond the scope of this study to consider details of 
interrelations among the different В and Τ subpopulations or concepts of 
helper and suppressor cell mechanisms. For a review of these subjects, 
reference 10. 
7.2 MATERIAL AND METHODS 
Of each experimental group, 4 to 9 animals (a total of 48 rats) were 
sacrificed at intervals of between 4 hours and 103 days after the start of the 
treatment. 
In addition to the experimental series, organs were collected from 4 animals 
treated with additional irradiation (400 cGy, 'd=20 cGy.min ) to the 
thymus and Peyer's patches. 
Six animals aged 2, 4 and 6 months served as controls to determine age-
dependent changes in the lymphatic tissues. Camoy-fixed specimens of the 
thymus, spleen, Peyer's patches and various lymph nodes, including 
paratracheal and mesenteric lymph nodes, were embedded in paraffin. Five 
μια thick sections were stained with hematoxylin-eosin, Goldner's tri-
chrome, PAS and pyronin-methyl green. 
7.3 RESULTS 
7.3.1 Thymus 
7.3.1.1 Normal histology (compare Fig. 7.4) 
The thymus of rodents histologically resembles that of the human neonate. 
The lobes of the gland are divided into lobules separated from each other by 
loose connective tissue. The organ is surrounded by a tender capsule 
consisting of 2 to 3 layers of connective tissue. The cortex and medulla are 
sharply defined. Cortical thymocytes are more densely packed and their 
nuclei stain more intense than do the thymocytes of the medullary region. 
The nuclei of epitheloid reticular cells are large and light stained. 
In contrast to the human thymus, those of rodents do not undergo age-
dependent physiological involution and Hassall bodies are hardly detec­
table in routine histological preparations (but can be observed under the 
electron microscope). Thus, an involution of the rodent thymus is accidental 
in every case and represents a pathological state that can be attributed to the 
treatment given. 
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Fig. 7.1 Thymus ai 4 hours after the ¡ast administration of cyclophosphamide (4 X 10 mg.kg ) . Cortex (C) righi lobule is 
more depleted than in the left. M medulla (60 X). 
Fig. 7.2 Thymus 4 hours after irradiation 900 cGy, ' d=20 cGy. min ) Extensive cell necrosis in cortex(C) andmedulla(M). 
(¡60 X). 
Fig. 7.3 Thymus one day after third treatment with cyclosporin A (30 mg.kg on alternate days)- Accumulation of 
macrophages (MA) indicates earlier damage to cortical thymocytes. Occasionally seen are a narrowed cortex (C). a densely 
populated medulla (M) and prominent epitheloid cells (250 X). 
(All sections pyronin-methyl green-stained). 
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7.3.1.2 Early changes (4 hours to 3 days) 
The administration of cyclophosphamide (4 X 10 mg.kg ) and ionizing 
radiation (900 cGy, ^ =20 cGy.min ) in the period of observation, i.e., in 
the interval of 4 hours to 3 days, results in necrosis of thymocytes in both the 
cortical and medullary areas. The extent of the necrosis is dose-dependent; 
it is independent of whether the drug mainly depressed either humoral or 
cell-mediated immune reactions. This also holds true for other drugs such as 
azathioprine and corticosteroids, compounds not included in this study. The 
decrease in weight of the thymus and changes in thymic microarchitecture 
reflect the loss of thymocytes. In most cases, the damaged thymocytes are 
phagocytosed by mononuclear cells, a population of cells which, in addition 
to epitheloid reticular cells, is normally present in the thymus. The number 
of macrophages was increased during the first 48 hours after both irradiation 
and administration of cyclophosphamide. 
Both drug- and radiation-induced involution of the thymus resulted in 
capsular and interlobular connective tissue infiltration by mast cells. 
Changes secondary to cyclophosphamide ( 4 X 1 0 mg.kg" ) (Fig. 7.1) 
The response of mononuclear macrophages to the cyclophosphamide 
treatment is less pronounced. The loss of thymocytes is first indicated by a 
moth-eaten appearance of the cortex and subsequent depletion of the 
cortical lymphocyte population. Initially, these changes are more pronoun­
ced in one lobule, while others still appear unaffected. 
Changes secondary to radiation treatment (900 cGy, ·ά=20 cGy.min"^) 
(Fig. 7.2) 
The occurence of necrosis of thymocytes in both cortical and medullary 
areas is most obvious. At four to five hours after the radiation treatment, 70 
percent of the cells are damaged, while the activity of macrophages is 
minimal. 
Changes secondary to cyclosporin A (30 mg.kg ) (Fig. 7.3) 
Throughout the cortex and the medulla, numerous macrophages showing 
ingested damaged lymphocytes are present Occasionally, hyperplastic 
cortical epitheloid reticular cells are seen to be arranged as islands. The 
dense population of the medulla suggests an increased uptake of thymocytes 
into the cortico-medullary shift. 
7.3.1.3 Late changes (one week and longer) 
The type and extent of late changes induced depends largely on the overall 
time in which the immunosuppressive regimen has been applied, the total 
dose administered and the combination of agents, respectively. 
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Fig. 7 4 Thymus 15 days aßer irradiation (900 cGy. d=20 cGy. m in ) Reco ven indicated by normal appeara псе of cortex 
(С) and medulla (M). (60 Χ). 
I total -1 Fig. 7.5 Thymus 103 days öfter standard immunosuppressive treatment (4 Χ ¡0 mg.kg cyclophosphamide and I 
lymphoid irradiation, 900 cGy. d=20 cGy.min ) and subsequent cyclosporin A (30 mg-kg on allemate days). Severe 
atrophy of thymus, differing densities of cortical (C) and medullary (M) thymocytes. 
Fig. 7 6 Hilar region of thymus at 37 days standard immunosuppressive treatment (see legend to Fig. 7.5) and subsequent 
cyclosporin A (20 mg. kg on alternate days). Equally dense populated cortex (C) and medulla (M). perivascular lymphatics 
packed mth small lymphocytes (above "M") (60 X/ 
(All sections pyromn-methyl green-stained). 
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7.3.1.4 Reconstruction of thymic microarchitecture (Fig. 7.4) 
At about 2 to 3 weeks after cyclophosphamide (4 X 10 mg.kg" ) and 
irradiation (900 cGy, ^=20 cGy.min ), the thymic microarchitecture is 
almost entirely reconstructed. The first signs of this reconstruction are the 
increased number of mitotic figures in cortical thymocytes. Proliferation of 
the thymocytes as indicated by the uptake of H thymidine is not restricted 
to the outer cortical region; it occurs with decreasing frequency as the 
central medullary region is approached. 
However, several mitotic figures appear to be abnormal during the early 
regeneration phase. The efflux of thymocytes and, hence, the functional 
recovery of the thymus, can be deduced from the overcrowding of 
perivascular lymphatic vessels, particularly in the hilar region of the 
thymus, with small lymphocytes. 
7.3.1.5 Complete atrophy (Fig. 7.5) 
Treatment according to the protocol (administration of cyclophosphamide 
(4X10 mg.kg ), a dose of radiation (900 cGy, ·ά=20 cGy.min ) and an 
immunosuppressive dose of cyclosporin A (30 mg. kg" ), s.c., on alternate 
days results in total atrophy of the thymus. The organ is shrunken, lost 
portions are replaced by adipose and dense connective tissue and the 
cortico-medullary architecture is abolished. The functional deterioration of 
the thymus is indicated by the inability of the rats to reject the tumor 
xenograft for up to 103 days after start of the treatment 
7.3.1.6 Abnormal patterns of thymus morphology ( all observations at day 
37 after starting the treatment) 
Conditioning of the rats with cyclophosphamide ( 4 X 1 0 mg. kg" ) and 
ionizing radiation (900 cGy, ·α=20 cGy.min" ) and with a reduced dose of 
cyclosporin A (20 mg.kg" , s.c, on alternate days) results in equalization of 
the thymic architecture (Fig. 7.6) Both the cortex and medulla are 
uniformly densely packed with small lymphocytes. The number of mitotic 
figures of these cells, however, remains low. The size of the thymus is 
distinctly reduced. 
The efflux of thymocytes from the thymus can be deduced from lymphatic 
vessels densely packed with small lymphocytes. The infiltration of the 
thymic capsule with mast cells is less obvious. This feature of the thymus is 
compatible with the capacity of the rats to reject a tumor xenograft (see 
Chapter 6). Omission of the radiation dose from the immunosuppressive 
standard protocol (cyclophosphamide 4 X 1 0 mg.kg" and cyclosporin A 
30 mg. kg" on alternate days s.c. only) resulted in the development of an 
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Fi& 7.7 Thymus at 37 days after cyclophosphamide (4 X ¡0 mg.kg' ) and subsequent cyclosporin A (30 mg.kg on 
alternate days). Follicle-like (F) structure (centwcytic type) in inner cortex (C) surrounded by prominent postcapillary 
venules (arrow), (250 X). 
Fig. 7.8 Thymus at 37 days after cyclosporin A (30 mg.kg on alternate days). 
Fig. 7.8a Several sharply defined nodules (N) composed of densely packed small lymphocytes in outer and inner cortex 
(60 X). 
Fig 7 8b Detail of central nodule of Fig. 7.8a, exhibiting accumulation of phagocytes (250 X). 
(All sections pyronin-methyl green-stained). 
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occasional follicle-like arrangement composed of cells resembling the 
centroblastic-centrocytic type, (Fig. 7.7), thus suggesting the influx into and 
development of В lymphocytes within the thymus. 
Postcapillary venules are prominent at the follicular border. Similar thymic 
changes reported in clinical and experimental immunopathology were not 
associated with the abolishment of T-lymphocyte competence. 
Continuous administration of cyclosporin A only (30 mg.kg every 48 
hours) resulted in the development of separate nodules of densely packed 
small lymphocytes (Fig. 7.8a). These nodules are located mainly in the 
outer cortical region of the otherwise cytologically equalized thymus. The 
nodules are surrounded by a rim of epitheloid reticular cells and occasio­
nally exhibit an increased number of large macrophages (Fig. 7.8b) with 
ingested lymphocytes. Though macroscopically the thymus remains shrun­
ken, the T-cell competence is indicated by the capacity of the animals to 
reject the tumor xenograft 
7.3.2 Peripheral lymphatic organs 
The microarchitecture and the condition of peripheral lymphatic organs 
depends on the effectiveness of the immunosuppressive treatment (drug, 
irradiation) and the capacity of central lymphoid organs to replace 
damaged components of the peripheral lymphatic tissue. 
Functionally, particularly for IgG synthesis, В lymphocytes are largely 
dependent on the presence of thymus-derived cells. A deficiency in the 
thymus lasting for long periods results in a decrease in the number of 
plasma cells in the B-cell compartments, e.g., in the medullary cords of 
lymph nodes. However, since IgM synthesis is T-cell-independent, plasma 
cells and their precursors may abundantly proliferate in the absence of a 
functional thymus but in the presence of suitable antigen. 
In the present study, only about 60% of the total bone marrow of the rat 
could be inactivated by the radiation dose and it could be depressed only 
transiently secondary to cyclophosphamide (myelodepressive side-effect). 
Therefore, it is to be expected that the regeneration of B-lymphocyte 
compartments might occur immediately after stoppage of drug admini­
stration. 
7.3.2.1 Lymph nodes 
7.3.2.1.1 Normal histology (Fig. 7.9) 
The microarchitecture of the lymph nodes in most species (for instance, in 
the rat, dog and man) is relatively uniform. In the outer cortex, the follicles 
form the border of the subcapsular sinus. The follicles are composed of 
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Fig 7 9 Lymph node of control rat kept under specific germ-free conditions. Follicles (F) without germinal center, densely 
populated paracortical area (PCA) and medullary cords (M) Note post capillary venules between "F" and "PCA"(60 X). 
Fig. 7 10a Lymph node at 20 days after cyclosporin A (30 mg kg on alternate days). Postcapillary venule (PC V) of inner 
PCA with cuboidal endothelium and surrounded by several blast cells. Efflux of lymphocytes via extension of medullary 
sinus (S), (250 x;. 
Fig 7.10b Lymph node at 103 days qfter standard immunosuppressive treatment (see legend to Fig 7.5) and subsequent 
cyclosporin A (30 mg. kg on alternate days). PCV with flat endothelium of inner PCA- Note lack of blast cells and 
sinusoidal efjflux (450 X / 
(All sections pyronin-methyl green-stained) 
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В lymphocytes. Within the primary compact follicle, germinal centers 
(secondary follicles) can develop secondary to an appropriate stimulus. 
Germinal centers are considered to generate plasma cells and B-memory 
cells. Rats kept under specific germ free conditions exhibit almost no 
germinal centers. 
The inner cortex (paracortical area) consists of diffuse lymphatic tissue 
composed of thymus-dependent cells. Triangular portions of the inner 
cortex might be interposed between the follicles and extend up to the 
subcapsular sinus. The medullary cords are packed with plasma blasts, 
plasma cells and В lymphocytes. 
In the lymph node, the postcapillary venules are provided with a cuboidal 
endothelium, a structure suitable for the entrance or re-entrance of 
circulating or recirculating lymphocytes. These may be either sensitized 
ones or their thymus- or bone marrow derived precursors. 
These types of postcapillary venules are found around the follicles, within 
the paracortical area and adjacent to the medullary cords. Sensitized 
lymphocytes also enter the organ via the regional lymphatic vessels 
through the subcapsular and the penetrating sinuses. 
Lymphocytes escape from the paracortical area mainly via the peripheral 
extensions of the medullary sinuses (Fig. 7.10a). 
7.3.2.1.2 Early changes (four hours to 3 weeks) 
The administration of cyclophosphamide (4 X 10 mg. kg" ) results in the 
necrosis of a fraction of the follicular lymphocytes. Several cells in the 
paracortical area are also damaged, while cells of the medullary cords 
remain intact After administration of a dose of radiation, the damage to 
follicular and paracortical cells is more extensive. 
At three to 5 days after a single intervention with either cyclophosphamide 
or irradiation, an increase in mitotic figures of blast cells indicates the 
reconstruction of Τ and В dependent regions. 
At one week after treatment, the follicles exhibit an occasional germinal 
center, while the lymphocytes in the inner cortex are concentrated in certain 
areas. The space between these areas contains few cells. 
The reconstruction phase is associated with both an increased influx of 
lymphocytes via postcapillary venules and a higher efflux of small 
lymphocytes via the medullary sinuses (Fig. 7.10a). Following irradiation, 
the final morphological recovery requires 3 to 4 weeks. 
Cell necrosis is almost absent after the administration of cyclosporin A. 
However, the accumulation of mast cells around and within the lymph node 
suggests catabiotic changes, while the reduction in size due to cellular 
depletion of the paracortical area indicates a negative balance of cellular 
homeostasis of Τ lymphocytes. 
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Fig. 7 11 Lymph node al 39 days after standard immunosuppressive treatment (see legend to Fig. 7-5) and subsequent 
irradiation of thymus (400 cGy, d=20 cCy.min ) on days 18. 25 and 36. Follicles (F) without germinal centers, largely 
depleted paracortical area (PCA) Medullary cords (M) enlarged and packed with plasma cells (60 X). 
Fig. 7.12 Lymph node at 37 days after standard immunosuppressive treatment(see legend to Fig 7.5) and cyclosporin A (30 
mg. kg on alternate days). 
Follicles (F) without germinal centers, small and generally empty PCA but with an occasional moderately dense cell 
accumulation. Note prominent postcapillary venule m empty PCA between "PCA" and "F". Medullary cords (M) small 
with few plasma cells (60 X). 
(All sections pyronin-methyl green-stained). 
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7.3.2.1.3 Late changes (three weeks or more) 
Since cyclophosphamide is administered only during the early phase of the 
immunosuppressive treatment, the microarchitecture of the lymphatic 
follicles, composed of В cells, remains mostly unaltered during the late 
experimental period. Germinal centers occasionally developed in animals 
following rejection of the tumor xenograft. While the condition of the 
paracortical area is largely dependent on the structural changes in the 
thymus induced by immunosuppressive measures, the morphological 
deterioration of the thymus-dependent inner cortex is not correlated with a 
deminished immunocompetence; the tumor xenograft was not rejected 
The paracortical area was depleted in most of the animals conditioned by 
cyclophosphamide (4 X 10 mg.kg" ) and by total lymphoid irradiation (900 
cGy) and subsequently subjected to irradiation of the thymus (400 cGy, 
•d=20 cGy.min ) on days 18, 25 and 36 (Fig. 7.11) (for severe atrophy of 
the thymus, see Fig. 7.5). In addition, most of the postcapillary venules had 
a flattended endothelium. Morphological indications of a lymphocyte influx 
and efflux were few. 
The additional irradiation of the thymus was associated with an accelerated 
rejection of the transplanted tumor. At the end of the observation period(39 
days), however, the medullary cords in lymph nodes were enlarged and 
densely packed with plasma cells, suggesting a transient immune deviation 
in favour of В cell descendents. 
Of particular interest were the changes resulting from long-term administra­
tion of the potent immunosuppressive agent cyclosporin A (30 mg.kg , 
every 48 hours). Without a conditioning treatment, the inner cortex 
exhibited a normal appearance at 37 days after administration of cyclospo­
rin A. The postcapillary venules were of the active type (compare Fig. 7.10a 
and, for the thymus, Fig. 7.8). 
In contrast, cyclosporin A given subsequent to the conditioning protocol 
(cyclophosphamide and a dose of radiation) apparently inhibited the 
reconstruction of the inner cortex, since the paracortical area remained 
small and deprived of cells. 
There was, nevertheless, an occasional diffuse, moderately dense accumu­
lation of cells of about the diameter of a normal lymphatic follicle (Fig. 
7.12). These accumulations of cells were present in lymph nodes at37 and 
103 days after the start of the treatment independent of whether the animals 
had received 20 mg. kg" or 30 mg. kg" of cyclosporin A every 48 hours and 
had thus regained the capacity to reject or not the tumor xenograft (see 
Chapter 6). 
It was remarkable that, even in animals bearing a large proliferating tumor 
xenograft for 103 days, the cell population contributing to the formation of 
local accumulations in the paracortical area was composed of large 
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Fig. 7 13 Spieen of control ral kept under specific germrfree conditions. Prominent, dense penartenolar sheath (PALS), 
small foliicies (F). with an occasional germinal center (GC). Distinct separation (arrow) offoiiiclefrom marginai zone 
(MZ). RP red puip (60 X)-
Fig, 7.14 Spleen at 29 days after standard immunosuppressive treatment (see legend to Fig 7.5) and irradiation of thymus 
(400 cGy. d=20cG}. min ) on days ¡8 and 25. PALS largely reduced in size and depopulated. Follicles (F). redpulp(RP) 
and marginal zone appear morphologically unchanged (60 X). 
(All sections pyronin-methyl green-stained). 
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pyroninophilic immunoblasts exhibiting numerous mitotic figures and 
medium-sized and small lymphocytes. The medullary cords of lymph nodes 
of rats treated with cyclophosphamide were not different in appearance 
from those of the control rats. 
In animals which had rejected a tumor xenograft, the number of plasma cells 
was slightly increased as compared with normal controls. 
7.3.2.2 Spleen 
7.3.2.2.1 Normal histology (Fig. 7.13) 
The white pulp of the spleen of rodents is characterised histologically by a 
prominentperiarteriolar lymphatic sheath(PALS). It surrounds the arteries 
of the pulp and its side branches, the central arteries, almost as a continuous 
tube. It is generally agreed that the lymphocytes of the PALS, particularly 
of its inner layer, are of the Τ type (18). Around the central artery, the 
lymphocytes are somewhat smaller and appear more closely packed than 
those of the proximal portion of the PALS. The follicles, composed of 
В cells, develop adjacent to central arteries. Secondary follicles (germinal 
centers) are not frequently observed in the spleen of animals kept under 
specific germ-free conditions. 
Both the follicles and the PALS are separated from an outer marginal 
("transitional") zone by a rim consisting of reticular ("metallophilic") cells 
and of capillaries which are fed at the follicular level by branches of the 
central artery. Cells of the marginal zone are mainly medium-sized 
lymphocytes, while the number of monocytes and macrophages varies 
considerably. 
Among rodent species, the marginal zone is most prominent in the spleen of 
the rat Compared with other species, including man, differences in the 
microarchitecture of the splenic white pulp are in quantity rather than in 
quality. 
In routine histological sections of the human spleen, for instance, the PALS 
appears more discontinuous because of the larger number of trabecular 
arteries which are not ensheathed by lymphocytes. 
In the normal spleen of rodents, plasma cells are arranged in small groups 
located close to trabecule that cross the red pulp. 
Scattered erythropoietic islands are also a normal feature. 
7.3.2.2.2 Early changes (4 hours to 3 weeks) 
After the administration of cyclophosphamide, necrosis of follicular cells 
was less obvious than in lymph nodes. The follicles were not even reduced in 
size. In the PALS, a slight increase in the number of macrophages suggested 
that some Τ cells were affected. However, the changes were irregularly 
distributed. Not only did adjoining follicles exhibit different degrees of 
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cellular necrosis but also the lymphocytes of particular segments of the 
PALS appeared to be more sensitive to cyclophosphamide than others. The 
small lymphocytes around the central artery were most resistant to injury. 
While the fraction of necrotic lymphocytes in both the follicles and the 
PALS was relatively high immediately after a dose of radiation, no distinct 
changes were noted as a result of the short-term administration of 
cyclosporin A . 
An indication of the reconstruction of the lymphatic tissue after various 
degrees of damage was the occurrence of blast cells within the follicular 
center and scattered throughout the PALS and accompained by an increase 
in the number of mitotic figures. 
During the reconstruction phase, particularly in animals which had rejected 
a tumor xenograft, many but not all follicles developed a germinal center. At 
the same time, the PALS had a patchy appearance and only became fully 
populated at about 3 weeks after the animals had been conditioned with 
cyclophosphamide (4 X 10 mg.kg ) and irradiation of lymphatic tissues 
(900 cGy, 0=20 cGy.min"1)· 
An occasional influx of non-B, non-T cells was indicated by the presence of 
megakaryocytes within the PALS. Furthermore, in animals obviously 
sensitized to tumor antigens (evidenced by rejection of tumor xenograft), 
plasma cells accumulated around the PALS but were also occasionally seen 
within the inner PALS. 
During the early reconstruction phase, the lymphatic vessels running within 
the hilar trabecular system were occasionally seen to be densely packed 
with small lymphocytes, suggesting an efflux and functional recovery. The 
number of erythropoietic islands was also increased considerably. 
7.3.2.2.3 Late changes 
Similar to the findings in the inner cortex of the lymph node, the condition of 
the PALS of the spleen depended on structural changes of the thymus which 
were induced by the type of treatment given in addition to the standard 
immunosuppressive conditioning. 
Again, the PALS was most depleted in animals first conditioned by 
cyclophosphamide (4X10 mg.kg ), total lymphoid irradiation (900 cGy, 
•d=20 cGy.min ) and subsequently submitted to additional radiation 
treatment of the thymus (400 cGy, ^=20 cGy.min" ) on days 18, 25 and 
36 (Fig. 7.14; compare with thymus in Fig. 7.5). However, there was an 
occasional segment around the central artery which was densely populated 
with small lymphocytes. 
The follicles in these animals were large but only few had a germinal center. 
The number of plasma cells was neither significantly increased nor 
decreased. 
Much more complex changes occurred secondary to the administration of 
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Fig. 7 15 Spleen al 37 days after cyclosporin A (30 mg. kg ) . Large follicles (F) vmh large, active germinal centers (GC). 
Peharienolar sheath (PALS) apparently extending bey ond central arteries (CA). Marginal zone (MZ) and red pulp (RP) 
unchanged (60 X). 
Fig. 7.16 Spleen at 20 day s after standard immunosuppressive treatmeni(see legend to Fig. 7.5) and subsequent cyclosporin 
A (30 mg. kg on alternate days) PALS largely depleted (left) partly ъ ι ih preserved inner sheath (right) or layer around CA 
(60 X). 
(All sections pyronin-methyl green stained). 
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Fig. 7.17 Spleen al 103 days after standard immunosuppressive treatment (see legend to Fig. 7.5) and subsequent 
cyclosporin A (30 mg. kg on alternate days). Periarteriolar sheath (PALS) largely, but irregularly depleted, with remnants 
particularly around central arteries (CA). Few small follicles (F). Marginal zone (MZ) unchanged 
Fig. 7.18 Spleen at 37 days after standard immunosuppressive treatmeni(see legend la Fig. 7.5) and subsequent cyclosporin 
A (20 mg. kg on alternate days). Lower cyclosporin dose resulted in irregular nodular repopulation of PALS and formation 
of large follicles (F). Marginal Zone (MZ) unchanged (60 У.). 
(All sections pyronin-methyl green-stained). 
i l l 
cyclosporin A with or without preceeding conditioning immunosuppressive 
treatment 
When cyclosporin A was used as the sole immunosuppressive agent, the 
spleen resembled a B-cell-stimulated rather than a T-cell-depressed one, as 
shown by the development of large germinal centers expanding the follicles. 
There was neither generalized nor local depletion of the PALS. In contrast, 
the terminal branches of the central artery had become ensheathed by small 
lymphocytes. (Fig. 7.15). 
As discussed earlier, the thymus of these rats exhibited an equalized 
structure and developed multiple nodules (Fig. 7.8). The animals receiving 
only CSA rejected the tumor xenograft; see Chapter 6. 
In cyclosporin A treated rats bearing no tumor graft and in animals 
submitted to the pretransplant conditioning protocol, the germinal centers 
were absent and the follicles largely reduced. 
The PALS also exhibited characteristic changes. Large portions of the 
proximal lymphatic sheath were either almost entirely depleted or exhibited 
a moth-eaten appearance, while the inner PALS around several arterial 
branches was still recognizable (Fig. 7.16). 
These changes were frequently observed at between day 20 and 103 after 
start of the treatment (Fig. 7.17). 
The influence of cyclosporin A on the morphological appearance of the 
splenic white pulp was clearly demonstrated by experiments where an 
obvious underdosage of cyclosporin A (20 mg. kg"1 instead of 30 mg. kg" ) 
was administered subsequent to the standard immunosuppressive protocol. 
Animals in which tumor xenograft rejection was delayed exhibited large 
follicles with an occasional germinal center in the white pulp of the spleen 
and a largely irregular reconstructed PALS with nodular appearance (Fig. 
7.18). 
7.3.2.3 Peyer's Patches 
7.3.2.3.1 Normal histology 
In contrast to the gut-associated lymphatic tissue consisting of transient 
lymph nodules, the aggregated lymph nodules of Peyer are well defined 
organs. 
These so-called patches of Peyer are composed of follicles (B cells) and an 
interfollicular thymus-dependent area. In contrast to the lymph nodes and 
the spleen, all follicles in rats kept under germ-free conditions exhibit a large 
germinal center and numerous "tingible body" macrophages. 
As identified according to the number of mitotic figures and the incoipo-
ration of tritiated thymidine, the main site of lymphocyte proliferation is not 
the germinal center but the subserosal portion of the lymphocytic corona. 
The opposite corona projects a conus- or dome-like portion into the 
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Fig. 7.19 Peyer's patch at 4 hours after the last administration of cyclophosphamide (4X 10 mg. kg ) . No cell necrosis in 
either densely and thinly populated(germinalcenter)area{DNA. TPA)orindome-shaped(D)andinterfolliculararea(IFA) 
(60 X). 
Fig. 7 20 Peyer's patch at 4 hours after total lymphoid irradiation (900 cGy. d=20 cGy. min ) . Extensive cell necrosis with 
subsequent reaction of macrophages throughout DPA. TPA and D (160 X). 
(All sections pyrontn-methyl green-stainedj. 
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Fig. 7 21 Peyer's patch ai 24 days aßer cyclosporin A (30 mg kg on alternate days) Microarchitecture of follicle 
exhibiting densely and thinly populated area (DPA, TPA) and dome-shaped area (D) is unchanged. 
Depletion of mtrafollicular area results in prominence of postcapillary venules (arrov,). (60 X). 
Fig. 7.22 Payer's patch at 37 days after standard immunosuppressive treatment (see legend to Fig 7.5) and subsequent 
cyclosporin A (20 mg kg on alternate days) Germinal center characteristics of TPA maintained by presence of "tingible 
body'' macrophages Mitotic figures also m DPA (250 Χ). 
(All sections pyronin-methy I green-stained) 
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intestinal lumen. This dome-shaped area is covered by a specialized 
intestinal epithelium capable of directing the antigen from the lumen 
towards the follicle. The dome-shaped area contains numerous plasma 
cells. 
Postcapillary venules are abundant in the interfollicular area, indicating 
that the patches of Peyer are involved in the recirculation of lymphocytes. 
7.3.2.3.2 Early changes (four hours to 2 weeks) 
Neither treatment with cyclophosphamide nor cyclosporin A resulted in the 
necrosis of lymphocytes- in contrast to the thymus, lymph node and spleen. 
Stimulated macrophages as indicators of accumulating cell debris were also 
absent (Fig. 7.19). 
Following total lymphoid irradiation, extensive necrosis of cells in the 
germinal center, the subserosal corona (Fig. 7.20) and the interfollicular 
area was observed. 
This loss of cells is quickly replaced, since in the 5 to 14-day specimen no 
significant changes as compared with controls were observed 
7.3.2.3.3 Late changes 
When thymic morphology was distorted, the interfollicular areas of Peyer's 
patches were largely depleted of cells, even after the administration of 
cyclosporin A only in a dose of 30 mg.kg s.c on alternate days. In this 
case, the germinal centers were shrunken, but not absent (Fig. 7.21). 
In animals treated with the standard immunosuppressive protocol and with 
cyclosporin A at 20 mg.kg instead of 30 mg.kg (Fig. 7.22), large 
germinal centers with numerous "tingible body" macrophages as well as a 
high mitotic activity of cells in the subserosal corona were observed. These 
rats had rejected their tumor xenografts; see Chapter 6. 
7.4 DISCUSSION 
The acute damage (four-hour specimen) to lymphatic tissue was particu­
larly severe after irradiation (900 cGy, ^ = 2 0 cGy.min ). 
The thymus, lymph nodes, spleen and Peyer's patches were affected almost 
to the same extent 
In contrast to after the treatment with radiation, the various lymphatic 
tissues responded differently to the administration of cyclophosphamide ( 1 
to4X lOmg-kg"1). 
No significant immediate changes secondary to cyclophosphamide were 
observed in the Peyer's patches. In the thymus, the necrosis of thymocytes 
was most obvious. Damage to both В and Τ cells in the lymph nodes and 
spleen was indicated by the occurrence of macrophages containing ingested 
cell debris and by a decrease in the size of follicles and the periarteriolar 
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sheath. The atrophy was far less severe, however, as compared to the 
atrophy reported after the administration of cyclosporin A at a dosage of 45 
mg.kg (X 4) in clinical pretransplant immunosuppression for bone 
marrow transplantation (12). Immediate morphological changes in the 
lymphatic tissues were minimal after the administration of cyclosporin A in 
a dose of 30 mg.kg on alternate days. In the present study, the bone 
marrow was partly spared in the irradiation fields, facillitating early 
repopulation of В cell areas. Hence, the immediate not too extensive loss of 
cells may be replaced by the influx of small lymphocytes of blood borne 
follicle repleting type almost within 24 hours (14). 
The development of germinal centers, however, is Τ cell dependent. Τ cells 
are normally present among the cells of the germinal which contribute to the 
pool of В cells involved in humoral immunity (20). 
These Τ lymphocytes appear to be of the helper cell type (18). 
It has been shown that in lethally irradiated rats the reconstitution with 
normal thoracic duct lymphocytes (T and В cells) leads to the formation of 
excellent germinal centers. An infusion of thoracic duct В lymphocytes, 
however, gave a negative result, indicating the dependency of germinal 
center formation on the presence of Τ cells. 
Reconstitution with bone marrow cells was also unsuccessful probably 
because of lack of functional Τ lymphocytes (15). The formation of 
germinal centers was occasionally observed in the present study. This was 
particularly so in conditioned animals exposed to the tumor antigens and 
which had regained the capacity to reject the grafted xenogeneic tissue, thus 
indicating the recovery of T-lymphocyte functions. 
The largest germinal centers were observed in the spleen, particularly in 
standard conditioned animals which rejected the tumor because of an 
insufficient dose of cyclosporin A. The prominent germinal center reaction 
suggests a central sensitization via the general circulation (10) following 
tumor transplantation. This is probably induced by tumor cells invading the 
vasculare (see Chapter 8). 
In contrast to the above findings, the rejection of the tumor graft was largely 
independent of the actual condition of the T-cell-dependent periarteriolar 
lymphatic sheath and/or the paracortical area. This was especially obvious 
in conditioned animals subjected to repeated local irradiation of the thymus 
(400 cGy, ^ = 2 0 cGy.mm l) on days 18, 25 and 36. 
Although the T-dependent areas were the most depleted as compared with 
those in animals of the other experimental series, these animals rapidly 
rejected the tumor after the first or second irradiation. However, plasma 
cells were developed in abundance; this suggested stimulation of the В cell 
system and a humoral response. Severe plasmacytosis of medullary cords 
as well as a depleted inner cortex has also been observed in patients 
submitted to treatment with antilymphocyte serum (7). 
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In the lymph node, the functional recovery from immunological injury was 
generally associated with an increase in active postcapillary venules and the 
efflux of small lymphocytes into the sinus system, indicating an increase in 
lymphocyte recirculation. 
Changes in the marginal zone in the spleen, the site of re-entrance of the 
lymphocytes (2), are significant. 
It is highly speculative at present to suggest that, in animals which failed to 
reject the tumor xenograft, locally proliferating cells in an otherwise 
exhausted paracortical area probably belong to the T-suppressor type. 
The same holds true for the periarteriolar sheath of the spleen which, 
particularly after long-term administration of cyclosporin A, exhibited a 
nodular appearance in tumor bearing animals. 
The present study largely confirmed the thymus dependency of the 
paracortical area (lymph nodes), the periarteriolar sheath (spleen) and the 
interfollicular area (Peyer's patches). 
These areas frequently remained depleted in animals with an "equalized" 
thymic structure secondary to cyclosporin A. Thus, cyclosporin A to an 
extent dependent on the dose administered appears to block certain T-
lymphocyte traffic rather than acting as a cytotoxic drug. 
Under normal circumstances, the thymus quickly recovers from accidental 
involution secondary to a single insult or to infections. Under certain 
conditions, however, the blood/thymus barrier apparently breaks down to 
allow cells other than Τ cell precursors and mononuclear macrophages to 
enter the thymus in which they also are capable of proliferation. 
Observations in rodents range from the establishment of myelopoiesis in the 
thymus secondary to splenectomy to the development of "thymomas" 
consisting exclusively of plasma cells (personal communication, Prof. Dr. 
CR Jerusalem, July, 1982). Of particular interest is the occurrence of 
lymphatic follicles within the thymus. Thymic follicles are found to be 
associated (cause or effect?) with diseases classified as autoimmune 
disorders, in cases of myaesthenia gravis and chronic agressive hepatitis in 
man and in AK mice during developing hemolytic anemia (11). 
In Swiss mice, thymic follicles with distinct germinal centers were 
recognized as the possible source of a malignant lymphoma histologically 
resembling Burkitt's lymphoma (8, 9). 
It remains an open question whether thymic follicles and nodules observed 
secondary to cyclosporin A administration are transient or may give rise to 
malignant transformation. 
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CHAPTER 8 
GROWTH AND REJECTION OF TUMOR XENOGRAFTS: 
HISTOLOGICAL AND IMMUNOLOGICAL ASPECTS 
8.1 INTRODUCTION 
More experimental data are needed to satisfactorily answer the relevant 
questions concerning tumor xenotransplantation, particularly with respect 
to maintenance of morphological characteristics, invasiveness and mitotic 
rates of the grafted tumor tissue in the new host ( 1 ). 
Urist(25) studied the morphology of human malignant tumors transplanted 
into athymic nude (nu/nu) mice. Similarity of the histological composition 
of the transplant to the original tumor was observed in four of twelve 
osteosarcomas and in four of five chondrosarcomas. The surviving tumors 
were seen to regress by the fourth week after transplantation without 
evidence of cell mediated immunity (25). If xenografting was to be used as 
an in vivo model in clinical studies for assessment of therapeutic responses, 
the transplanted tumor should behave as the tissue of the donor, but its 
constituent cells should also proliferate for much longer times. 
The model of tumor xenotransplantation presented here was employed to 
analyse the pre- and posttransplantation morphology of the two tumors 
(mouse osteosarcoma and human adenocarcinoma). In addition, it was 
attempted to distinguish between spontaneous regression and rejection. 
8.2 MATERIAL AND METHODS 
A total of 24 tumor grafts (14 osteosarcomas and 10 adenocarcinomas) 
were investigated histologically. 
The specimens were obtained by either wedge biopsy, taking care to excise a 
whole segment (under ether anesthesia), or following of sacrificed animals 
at between 7 and 103 days after transplantation. Two tumor grafts at 64 and 
103 days posttransplantation were examined under the electron micrscope. 
Fragments of donor tumor tissue excised for xenografting served as 
controls. For a description of the techniques of preparation and staining of 
histological sections, see Chapter 7. 
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Histology of the mouse C22LR osteosarcoma and human adenocarcinoma before and after transplantation of tumor fragments 
in conditioned Wistar rats. 
Fig 8 1 Osteosarcoma pretransplantation histology. Characteristics absented are those of a fibrosarcoma rather than an 
osteosarcoma (Hematoxylin and eosin, 60 X). 
Fig 8.2 Osteasarcoma at 1Ì days after successful xenotransplantation. Charactenstics of fibrosarcoma are maintained 
Note absence of host cellular infiltrates within encapsulating tissue and around vein draining the lumor( arrow) and absence 
of local necrosis in this specimen (Hematoxylin and eosin, 60 X). 
Fig 8.3 Higher magnification of the border of tumor xenograft showing high mitotic activity (arrows) anda host arteriole 
penetrating the tumor tissue (star). (Pyrvnin-methyl green, ¡60 X). 
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8.3 RESULTS. HISTOLOGY OF THE TUMORS BEFORE AND AFTER 
TRANSPLANTATION 
8.3.1 Pretransplantation and posttransplantation tumor histology 
8.3.1.1 The mouse osteosarcoma 
8.3.1.1.1 Pretransplantation appearance (Fig. 8.1) 
The mouse osteosarcoma (C 22LR) originally arising in 1958 in the 
(C57BL/Rij X CBA/Rij) Fj hybrid has changed on transplantation into 
syngeneic animals into a poorly differentiated fibrosarcoma It initially 
consisted of a considerable amount of anaplastic cells with marked 
variations in size and shape. Giant cells were infrequent 
The tumor cells were characteristically arranged in bands and strands 
running in divergent directions (fish draught pattern). 
The neoplastic cells were distincdy pyroninophilic and the nucleus exhibi-
ted 3 to 5 nucleoli. Scattered small bundles of collagenous fibrils were found 
between the anaplastic cells. 
The tumor was provided with a moderate number of capillaries. 
Its margins were poorly defined because of a lack of encapsulation and the 
tendency to extend into the surrounding tissue. The sarcoma cells infiltrated 
the subcutaneous tissue, fasciae and nerves and less frequently the walls of 
blood vessels. The overall mitotic activity was high, ranging between 2 and 
4.5 per cent No areas with focal necrosis were evident 
8.3.1.1.2 Posttransplantation proliferation phase (7-13 days) 
The fibrosarcomatous feature of the tumor as well as the percentage of 
mitotic figures were maintained The cells appeared more uniform in size 
(Figs. 8.2 and 8.3). The amount of collagenous fibers varied locally. 
Remnants of infiltrated subcutaneous connective tissue were hardly dis-
tinguishable from fibers produced by sarcoma cells. Many sinus-like small 
veins were present Immunocompetent cells failed to infiltrate the tumor. In 
large tumor nodes (i.e., tumors with a diameter greater than 10 mm) 
scattered foci of ischemic necrosis were evident Necrotic areas were 
characteristically located between the supplying blood vessels, but vascular 
changes were notably absent During the later growth phase, the tumor 
became encapsulated by dense collagenous tissue. Necrotic areas were 
more frequent and they had increased in size and were occasionally 
infiltrated with polymorphonuclear neutrophils. 
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Fi& 8.4 Human adenocarcinoma, preiransplaniation histology. Small central necrosis of three adenoid lobules (center of 
picture). Tumor cells invading host striated muscle tissue are surrounded by lymphocytes (right). (Hematoxy lin and eosin. 
60 X). 
Fig 8.5 Human adenocarcinoma at ¡03 days after successful xenotransplantation. Central portion of graft with slightly 
increased stromal connective tissue. Small central necrosis at middle right of picture. Open vessels (arrow) and absence of 
infiltration with host cells. (Hematoxylin and eosin, 60 X). 
Fig 8.6 Higher magnification of tumor xenograft showing high mitotic (arrows) activity in more solid peripheral portion of 
carcinoma (Pyronin-methyl green, 250 X). 
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Fig. 8 7-9 Adenocarcinoma al 103 days after successful xenografting. 
Fig. 8.7 Prohferaling capillary (С) at siroma/tumor (TU) junction; F.B. endothelial bud: E. endothelial cell P. pericyte: F. 
fibroblast, CO. collagen (3.700 X). 
Fi& 8-8 Degenerating lymphocyte (LY) within tumor cell (TV). (5. 600 X). 
Fig. 8 9 Intact neutrophilic granulocytes (NG) al stroma/tumor junction (3. 600 X). 
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Fig 8.10-11 Adenocarcinoma at 103 days afier xenogrqfting. 
Fig, 8.10 Cluster of tumor cells v.ithtn small vein (star). Amorphous PAS positive material (arrow) in interstices, 
(PAS. 450 X). 
Fig, 8,11 Central portion of ¡umor In a connective tissue strand of the stroma, several multinucleated giant cells 
occasionally engaged in phagocytosis of PAS positive material (stars). Note the absence of ir\fìitrating cells. 
(PAS. 450 X). 
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8.3.1.2 Adenocarcinoma 
8.3.1.2.1 Pretransplantation appearance 
The human sigmoid colon adenocarcinoma was surgically removed from a 
male patient in 1978 and propagated in nude mice. 
Small en large clusters and cords of epithelial cells were arranged either in 
solid (mainly peripherally) or acinar glandlike structures (centrally) (Fig. 
8.4). Some pleomorphism was evident because of variations in cellular and 
nuclear size and in the pyroninophilia of the cytoplasm. The nuclei 
displayed either one large or up to 5 smaller nucleoli. In local accumulations 
of small tumor cells, the number of mitotic figures was about 8 per cent 
Necrosis of centrolobular carcinoma cells was infrequent The strands of 
connective tissue stroma were small in the periphery but larger in the center 
of the tumor. The stroma was rich in pyroniiiophilic fibroblasts, contained 
bundles of collagenous fibrils and displayed numerous arterioles, capilla-
ries and veins. The growth of the tumor was mainly expansive but also 
locally infiltrative. 
8.3.1.2.2 Posttransplantation proliferation phase (24 days to 103 days) 
The tumor in the conditioned rats exhibited essentially the same features as 
described for the pretransplantation specimen (Fig. 8.5). The incidence of 
central necroses did not increase nor did the number of mitoses and the 
pattern of vascularization did not change. Cords of tumor cells tended to 
infiltrate the striated muscle layer of the abdominal wall. Although loose 
accumulations of lymphocytes were occasionally present necrosis of 
adjacent tumor cells was notably absent In the more solid formations of the 
tumor periphery, the number of mitotic figures remained high even after 103 
days of transplantation (Fig. 8.6). In addition, mitotic figures of the vascular 
endothelium and, at the ultrastructural level, the proliferation of capillary 
buds (Fig. 8.7) indicated the excellent condition of the tumor graft 
Lymphocytes were occasionally seen invading a tumor cell (emperipolesis) 
but showed necrosis rather than damaging the xenogeneic cell (Fig. 8.8). In 
contrast, neutrophilic granulocytes were more numerous and cytologically 
intact (Fig. 8.9). 
At times, clusters of tumor cells were seen invading the vessels of the tumor 
(Fig. 8.10). The longer the tumor graft survived, the denser the stromal 
connective tissue. In several tumor grafts, multinucleated giant cells were 
engaged in the phagocytosis of PAS-positive material (Fig. 8.11). 
8.3.2 Rejection of the tumor xenograft 
Rejection is the inevitable fate of tumor xenografts in hosts not treated or 
insufficiently treated with cyclosporin A subsequent to the standard 
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Fig 8 12-14 Osteosarcoma al 9 days qftertransplaniation into rats conditioned by standard immunosuppressive treatment 
(see legend to Fig 7.5). No subsequent cyclosporin A 
Fig. 8 12 Mural thrombus (star) coiered by neutrophils. Remnants of neutrophils replacing absent endothelium (250 X). 
Fig 8 13 Layered thrombus with neutrophils (star) between first and subsequent fibrin deposit Numerous neutrophils 
(arrows) are attached to or have replaced damaged endothelium at the site of priman thrombus formation (250 У.) 
Fig. 8 14 Small vessel occluded by thrombus exhibiting initial pavementing of neutrophils (450 X). 
(All sections stained with Hematoxylin and eosin). 
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immunosuppressive protocol (see Chapter 6). 
Later repeated irradiations of the thymus of tumor bearing animals did not 
inhibit rejection of the xenograft; on the contrary, this procedure appeared 
to accelerate the regression of the transplanted tumor. 
Repeated irradiations of the thymus caused only severe depletion of 
thymus-dependent areas of the peripheral lymphatic tissue (see Figs 7.11 
and 7.14). 
Before the mechanisms of xenograft rejection are discussed, it should be 
noted that the initial stages of immunological destruction took place in the 
absence of detectable numbers of immunocompetent cells such as lympho-
cytes and mononuclear cells (macrophages). Lymphocytes and plasma 
cells accumulated in large numbers in the tumor encapsulating host tissue 
and in small numbers in the stroma of the transplanted adenocarcinoma, 
only when large portions of the tumor graft were already destroyed. 
Two main patterns of tumor xenograft destruction could be distinguished. 
The first was seen primarily in the rapidly growing osteosarcoma trans-
plants. Tumors measuring about0.5 totl.5 cm in diameter became softened 
as judged by palpation at the end of the second week after transplantation. 
Histologically, the center of these grafts was entirely necrotic and occasio-
nally heavily infiltrated with neutrophilic granulocytes. The rim of the 
tumor, however, consisted of 5 to 20 layers of intact and highly proliferating 
tumor cells. Accumulations of plasma cells and lymphocytes in the 
surrounding host granulation tissue were few. 
This type of necrosis is generally a feature of rapidly growing tumors, also in 
syngeneic animals. It suggests delayed proliferation of tumor vessels 
resulting in the necrosis of central tumor cells due to a lack of blood supply, 
while the peripheral cells are fed through diffusion from capillaries of the 
host granulation tissue. 
In the model discussed here, an immunologically triggered reaction, 
however, is not excluded. 
The second type of tumor xenograft destruction which resulted in tumor 
rejection was initiated by a characteristic vascular lesion, as suggested from 
serial studies of osteosarcoma xenotransplants. At branching points of 
larger vessels, mural thrombi developed secondarily to an endothelial lesion 
(Fig. 8.12). The thrombi were frequently covered by a layer of neutrophilic 
granulocytes giving rise to a progression of thrombus formation (Fig. 8.13) 
and finally to the occlusion of larger vessels. The initial endothelial lesion 
was always associated with the presence of neutrophilic granulocytes which 
were either attached to or had replaced the damaged endothelium (Fig. 
8.13). Also prior to trombosis, smaller vessels exhibited a characteristic 
pavementing of neutrophils (Fig. 8.14). 
The vessels of the outer periphery of the tumor located approximately 0.1 to 
0.2 mm beneath the host granulation tissue were remarkably free of this 
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Fig. 8.15 Osteosarcoma at ¡ I days after transplantation into rats conditioned by standard immunosuppressive treatment 
(see legend to Fig. 7.5). No subsequent cyclosporin A Ischemic necrosis of tumor tissue secondary- to thrombosis of small 
vessel branching from large vessel (arrows), (Gainer's trichrome. 80 X). 
Fig, 8.16 Osteosarcoma at 15 days after transplantation into standard-conditioned rats. No subsequent cyclosporin A. 
Dense accumulation of lymphocytes (accompanying plasma cell cannot be distinguished at this magnification) at the 
host/tumor border (nght). From the contralateral side (left), host granulation tissue cells have started to remove cell debris. 
Note the ingrowth of vessels (arrows), (Hematoxylin and eosin, 60 X). 
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Fig 8.17 Adenocarcinoma at 37 days afterxenolranspianiatton into rats conditioned by cyclophosphamide on!} (4 X 10 
mg-kg ) and subsequently treated with cyclosporin A (30 mg. kg on alternate days). Damaged capillary packed with 
neutrophils (arrows). Neutrophils migrate into already necrotic tumor tissue (star). (Hematoxylin and eosin. 250 X). 
Fig, 8.18 Adenocarcinoma at 37 days qfter xenotransplantation into rats treated exclusively with cyclosporin A(30 mg.kg 
on alternate days). 
Center of picture shows ghosts of tumor cells embedded in an amorphous substance. Note the absence ofpyroninophilic cells 
and macrophages. Debris of neutrophils (arrow) probably at wall of damaged vessel. (Pyronin-methyl green, 450 X). 
Fig 8.19 Adenocarcinoma at 3 7 days qfter xenotransplantation into control rats. Multinucleated giant cells(stars) engaged 
in the phagocytosis of amorphous (PAS positive) material. Lymphocytes (right half of picture) are distant from site of 
rejection, (Pyronin-methyl green 450 X). 
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lesion. The same was true for vessels running from the capsule into the 
tumor tissue (compare Fig. 8.2). 
Ischemic necrosis of tumor tissue occured secondarily to thrombotic 
occlusion of vessels (Fig. 8.15). On advancement of thrombotic events and 
confluence of local necrosis, the tumor was entirely destroyed during the 
subsequent two to three days. Only at this time were small cuffs of 
lymphocytes seen to develop locally around vessels of the host granulation 
tissue. During the ensuing days, plasma cells also increased in number and 
the lymphocytes started to invade the necrotic tumor (Fig. 8.16). 
The human adenocarcinoma xenograft was apparently rejected according 
to a type two mechanism. Neutrophils were seen also to accumulate in more 
peripheral capillaries (Fig. 8.17), while mononuclear cells (lymphocytes, 
macrophages) were absent within the tumor tissue undergoing necrosis 
(Fig. 8.18; compare Fig. 8.11). Multinucleated giant cells were present for 
long periods, also in necrotic tissue (Fig. 8.19). 
Dense accumulations of lymphocytes restricted to the host granulation 
tissue were only a postrejection phenomenon. These accumulations of 
lymphocytes were also observed in human adenocarcinoma xenografted 
into untreated recipients (Fig. 8.19). 
8.4 DISCUSSION 
In the immunosuppressed host, the posttransplantation phase of the two 
lines of tumor xenografts tested was histologically characterized by high 
proliferation rates of the neoplastic cells. The grafts showed all histological 
characteristics of the original tumor up to an observation period of 103 days. 
Early spontaneous vascularization of the grafted tumor tissue and 
simultaneous growth of vessels within the tumor enhanced the initial rapid 
increase in tumor mass. An occasional ischemic necrotic area of tumor 
tissue at the border between two circulation areas was apparently caused by 
an insufficient vasculature and is a common phenomenon in tumors with a 
short volume doubling time. In larger areas in which "spontaneous" 
necroses occured, however, the involvement of immune reactions is not 
excluded. 
The lack of immunocompetent cells, however, and the type of the initial 
lesion observed suggested that early rejection of the tumor was mediated by 
mechanisms different from those usually ascribed to tumor graft destructioa 
Several investigators have accumulated a large amount of basic data on 
tumor immunology and manifestations of host reactions against sponta­
neously arising or transplanted tumors. The result is a kaleidoscopic picture 
of possible reactions which cover all previously known effector mechanisms 
of the immune response. Indirect evidence for the importance of the Τ cell 
system in tumor rejection is derived from reconstitution experiments in 
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either congenital athymic of lethally irradiated rodents (17, 20). 
It has been shown that there is a correlation between histological recon­
struction of lymphoid host tissue and tumor rejection ( 12), BCG treatments 
to stimulate antitumor activity mediated by Τ cells (2) and destruction and 
concomitant host cell infiltration of tumor xenografts (13). 
Cellular reactions against tumors were found to depend on cells carrying 
theta antigen (22). It is generally agreed that cell-mediated immunity is 
effected by Τ lymphocytes that act directly to incapacitate or destroy tissues 
bearing foreign antigens ( 16). Loveland et al. ( 14), however, stressed that, 
in spite of many experiments supporting the concept that Τ cytotoxic cells 
(Tc) induce graft rejection in vivo, there is little evidence that Tc cells play 
the only role, a major role or no role in graft rejection in vivo. 
The interpretation that graft rejection is independent of Tc is based on 
experiments with skin grafting. A major role of Tc in tumor graft destruction 
remains questionable, since some of the data point to tumor rejection 
mediated by natural killer cells (4, 5), macrophages (18, 23, 24) or 
antibody-dependent cell cytotoxicity (21). 
The vast amount of data on lymphocytes and macrophages involved in 
immune responses has tended to overshadow the importance of previous 
findings, particularly regarding the role of humoral responses and that of 
neutrophilic granulocytes in the enhancement of cell destruction. The 
effector system of the humoral reaction involves specific antibody and 
complement The reaction can be explosive ( 3 ); as demonstrated in vitro on 
treatment with IgG plus complement, virtually all Krebs ascites tumor cells 
displayed remarkable cytoplasmic swelling in less than 2 minutes (7, 8). 
After 15 to 20 minutes, the normal cytoplasmic organization was disrupted. 
Neutrophils activated by the antibody-complement complex were able to 
accelerate the damage to target structures apparently by a mechanism 
similar to that of activated macrophages. Keller (10) argued that neutro­
phils could participate in the elimination of tumor cells, especially under 
circumstances where the number of conventional effector cells is limited 
In hyperacute rejection of organ transplants, the pavementum pattern of 
neutrophils is considered to be the histological indication of the prior 
binding of both antibody and complement to endothelial surface antigens 
(9). The possible rol of antibody in tumor destruction has been recently 
reconsidered (15). 
In the present study, both the morphology of the graft rejection and the 
reactivity of В lymphocyte areas in peripheral lymphatic tissues suggest a 
possible role of antibody in the rejection of tumor xenografts. In secondarily 
vascularized grafts of tumor tissue, the target of the humoral reaction is 
apparently directed not only against the xenogeneic tumor cells but also, as 
in the primarily vascularized organ transplant (6, 19, 26), against vascular 
endothelium. 
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As a result of endothelial damage, platelets adhere to the created rough 
surface and initiate a cascade of events which result in either mural or 
occluding thrombosis of vessels. This immune mechanism explains, on the 
one hand, the rapid loss of tumor cells, the type of necrosis and the decrease 
in size of the tumor and, on the other, gives rise to the supposition that the 
attacked vessels originate from the transplanted tumor and not from the host 
tissue. 
The absence of thrombotic changes in the outer thin layer of the tumor can 
be explained by the lack of foreign antigens on the endothelial surface of 
vessels penetrating the tumor border from the surrounding host granulation 
tissue. 
The sequence of events suggests that the primary immune reaction is 
directed against the tumor vasculature and that the lymphocyte and plasma 
cellular reactions are secondary to the massive release of tumor antigens 
due to the initial ischemic necrosis triggered by the vascular lesion. 
Sensitization against tumor antigens may occur centrally in the spleen after 
spontaneous revascularization by tumor fragments (Fig. 8.10) or periphe-
rally by recirculating lymphocytes. These data agree nicely with the 
observation that cyclosporin A largely depresses complement-dependent 
cytotoxicity (11). It is not known whether cyclosporin A suppresses the 
synthesis of T-helper-cell dependent antibody (for instance, IgG) and/or T-
independent antibody (IgM). This is perhaps a topic for further studies in 
attempts to improve immunosuppressive protocols for tumor xenotrans-
plantation. 
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CHAPTER 9 
TOXICITY AND SIDE-EFFECTS OF THE 
IMMUNOSUPPRESSIVE TREATMENT 
9.1 UROTHELIAL TOXICITY OF CYCLOPHOSPHAMIDE 
The extensive use of cyclophosphamide in clinical practice and in research 
has led to a thorough understanding of its toxicity. One of the metabolites of 
cyclophosphamide, acrolein, is probably the compound which causes 
urothelial toxicity (12, 13, 14). After cyclophosphamide treatment the 
entire urinary tract epithelium is in principle exposed but the extent of the 
damage depends on the time of exposure to acrolein. Even repeated low 
doses(<1.5 mg.kg ) of cyclophosphamide can cause hemorrhagic cystitis 
in humans (2,24,29). Excessive doses(> 15 mg. kg" ) of cyclophosphamide 
can result in severe edema and hemorrhage of the bladder mucosa which 
progress to hemorrhagic urocystitis with mucosal ulceration( 13). Repeated 
high doses of cyclophosphamide can result in bladder fibrosis. 
When cyclophosphamide is administered in addition to irradiation, the 
damage induced is particularly severe. 
Several authors have mentioned that cyclophosphamide can cause cancer 
of the bladder (10, 11, 16, 17, 30). The extent of damage depends on the 
time of exposure and the concentration of acrolein. 
The local toxicity of acrolein can be diminished by decreasing the 
concentration of the compound by a high fluid input and the administration 
of 2-mercaptoethane sulfonate sodium (Mesnum) to inactivate acrolein 
(6). 
In the rat model presented in this thesis, a histological study of the bladder 
mucosa revealed no evidence of damage to the urinary bladder epithelium 
after treatment with cyclophosphamide (4 X 10 mg.kg ) or cyclophos-
phamide^ X 10 mg.kg ) and total lymphoid irradiation(900 cGy, -0=20 
cGy.min ) after 7 and 14 days, respectively. 
It is concluded that no significant urothelial toxicity due to cyclophos-
phamide is detecable in the rat model described 
9.2 NEPHROTOXICITY AND HEPATOTOXICITY OF CYCLOSPORIN A 
9.2.7 Introduction 
Cyclosporin A has been suggested to prevent or diminish the host versus 
graft reaction in human organ transplantation. 
In addition, a lack of obvious myelotoxicity was observed (3, 4, 5). Pilot 
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studies in man, however, are suggestive for a dose-related nephrotoxicity 
and hepatotoxicity of this drug. 
In patients treated with allogeneic bone marrow for aplastic anemia, renal 
toxicity due to cyclosporin A was not found to be a problem (19). However, 
severe complications, including vascular injury and acute tubular necrosis, 
have been claimed to result from cyclosporin A administration in patients 
treated with allogeneic marrow for acute lymphocytic and myelogeneous 
leukemia, respectively (31). In recipients of cadaver kidney and liver 
allografts, nephrotoxicity of cyclosporin A was indicated by a reversible 
increase in blood urea and creatinine (7,19, 22, 28). The problems thus far 
encountered may be attributed to the difficulty in discriminating between a 
sufficient dosage of the drug, required for adequate immunosuppression, 
and inadequate or excessive dosages resulting in deterioration in renal 
functions (21). 
The evaluation of a possible nephrotoxicity due to cyclosporin A after both 
bone marrow and renal transplantation is complex because renal dysfunc­
tion develops frequently and may be influenced by antibiotics, antineo­
plastic agents, liver disease and septic or cardiogenic shock (31). Changes 
in renal functions in liver transplant recipients with excellent primary 
function of the graft permit conclusions to be drawn about the nephrotoxi­
city of cyclosporin A (22). 
These data, however, do not reveal whether long-term administration of 
cyclosporin A could lead to structural and therefore possibly irreversible 
renal damage (32). 
In the Sprague-Dawly rat, the administration of 25 to 50 mg.kg every 48 
hours for 21 days resulted in neither histological and ultrastructural 
observations of damage nor in an increase in urinary NAG (N-acethyl-β-D-
glucosaminidase), indicating the absence of damage to renal tubular cells. 
Secondary to the administration of 100 mg.kg of cyclosporin A, a 3-fold 
increase in serum urea associated with lack of weight gain and mild hair loss 
were the major changes observed; these effects were totally reversed within 
3 weeks after termination of cyclosporin A treatment (33, 34). 
The present study of tumor xenotransplantation in which the drug cyclos­
porin A was used as an immunosuppressive agent offered the possibility to 
investigate whether this drug may cause nephrotoxicity and hepatotoxicity. 
9.2.2 Material and methods 
In the interval of 3 to 103 days after start of treatment with cyclosporin A 
only or cyclosporin A at 30 mg. kg administered on alternate days in 
addition to the standard immunosuppressive protocol (i.e., cyclophos­
phamide 4X10 mg.kg and total lymphoid irradiation with a dose of 900 
cGy), 29 left kidneys and livers of the treated rats were collected for 
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histological examination. For routine histology, the Camoy-fixed organs 
were embedded in paraffin and 5 jum thick sections were stained with 
hematoxylin-eosin, Goldnei's thrichrome, PAS (periodic acid Schin) and 
pyronine-methyl greea 
For ultrastructural investigations, specimens were selected after a period of 
treatment of 24 days (cyclosporin A) and after 64 and 103 days (standard 
protocol with subsequent cyclosporin A regimen). 
Glutaraldehyde (2 per cent) fixed small specimens were postfixed in 
osmium tetroxide (2 per cent) and embedded in Epon 720. 
Semithin sections were stained with toluidine blue and ultrathin sections 
from selected areas were contrasted with lead citrate and uranyl acetate. 
9.2.3 Results 
9.2.3.1 Histology: kidney 
Tubular and glomerular capillary changes were notably absent at 24 and 64 
days after cyclosporin A administratioa Juxtaglomerular cells and afferent 
arterioles were prominent In PAS stained histological sections and 
particularly in toluidine blue stained semithin sections, the afferent arterio-
les exhibited an increased number of granular epitheloid cells. In controls, 
the number of epitheloid cells was only 1.9 per cent 
The percentage of arterioles with granular epitheloid cells as well as the 
number of granular epitheloid cells per arteriole increased significantly up 
to 72.2% during the first 64 days of cyclosporin A treatment After 103 
days, the glomerular tufts occasionally appeared to be condensed by 
narrowed capillaries, prominent PAS-positive mesangium and partial loss 
of the space of Bowman was observed There were no indications, however, 
of hypercellularity or crescent formatioa The peritubular connective tissue 
was slightly increased around several nephrons. 
9.2.3.2 Histology: liver 
In semithin sections obtained at 64 and 103 days after the start of the 
immunosuppressive treatment, several hepatocytes exhibited fatty chan-
ges. The liver cells displaying either one large or, more frequently, several 
small fat vacuoles were regularly distributed throughout the lobule, with 
somewhat higher numbers in the periportal region (Rappaporfs Zone I). 
Hepatocellular necrosis, either centrally or peripherally, was notably 
absent 
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Fig, 9 1-2 Histological sections of the Ιφ kidney ofa Wistar rat treated •niih ¡he slandard immunosuppressive arolocol 
(cyclophosphamide, 4 X 10 mg, kg . a dose of radiation, 900 cGy. d^lOcGy.mm and cyclosporin Λ 30 mg. kg s.c. on 
alternate days for 64 days). 
Fig. 9 1 Glomerulus with prominent granular epitheloid cells (EC) extending into the glomerulus. Normal glomerular 
capillaries (GC) and occasionally prominent podocyies( PO) Proximal comoluiion with dense lysosomes( PC) and normal 
distal convolution (DC) (900 X/ 
Fig, 9 2 CE, ceninole: N. nucleus; GO. Golgi complex; Gl. granule assembled by Golgi complex; G2. large granule. CR, 
cnnophagy (22.000 X). 
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Fig. 9.3-4 Histological sections of the ie/l kidney of a Wistar rat treated with the standard immunosuppressive protocol and 
cyclosporin A (see legend to Fig. 9.1-2) administered on alternate days for ¡03 days. 
Fig. 9 3 Mesangial cell (ME) producing increased basement membrane material (BM). Cytoplasmic extensions (EX) of 
ME split BM. 
EN. bulging endothelial celi PD. podocyte (7.200 X). 
Fig. 9 4 Irregular thickening of basement membrane(BM) of proximal convolution and of glomerular membrane(GM) L· 
lysosomes increased in number. EP. ßat glomerular epithelium, PO. podocyte (6.200 X). 
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9.2.3.3 Transmission electron microscopy, kidney 
The pre-, intra- and postglomerular vessels were free of microthrombotic 
and trombotic events at 24 to 103 days after cyclosporin A administration. 
The ultrastructure of the endothelium appeared normal in the 24 and 64-day 
specimens. The foot processes of podocytes were slender and did not tend to 
fuse (Fig. 9.1). 
In the afferent arterioles, the number of granular epitheloid cells was higher 
than expected from the light microscopical picture. Granular epitheloid 
cells exhibited centrioles and some of the granules were seen to be 
assembled by the Golgi complex, while others underwent crinophago-
cytosis (Fig. 9.2). After 103 days, the granulated epitheloid cells tended to 
extend into glomerular tufts, resulting in pseudoarteriolization of proximal 
capillaries. Increasing amounts of basement membrane (BM) material was 
laid down by mesangial cells and resulted in either bud-like and bizarre 
deposits or the splitting of the central portions of the BM (Fig. 9.3). 
The normally flat peripheral portions of the endothelium were locally 
thickened, while the nucleus and some surrounding cytoplasm protruded 
into the capillary lumen in a mushroom-like fashion. At sites of peripheral 
splitting of the BM, the foot processes of podocytes were frequently fused 
and the cytoplasm provided with dense accumulations of microfibrils. 
Swelling of mesangial cells and their close contact with the squamous 
parietal epithelium were the ultrastructural equivalents of the loss of the 
space of Bowman as recognized under the light microscope. 
The basal lamina (of Bowman) of the renal corpuscle and the BM of 
adjacent proximal convoluted tubules were locally thickened (Fig. 9.4). 
A lumpy-bumpy appearance and splitting of the endothelial BM of 
interstitial and afferent arterioles was also noted. 
In the proximal convoluted tubules, the number and the size of lysosomal 
structures increased gradually during the observation period. After a period 
of 103 days, the epithelium also exhibited a larger number of vacuoles. 
Several mitochondria were swollen and the cristae were occasionally 
disintegrated There were no indications, however, of cellular necrosis. 
9.2.3.4 Transmission electron microscopy: liver 
Hepatocytes containing large fat vacuoles had normal mitochondria and 
normal rough and smooth endoplasmic reticulum. 
The assembled fat(low density type) exhibited an occasional myelin figure. 
In the 64 and 103-day specimens, the portal and the adjacent interlobular 
connective tissues were slightly increased. No indications of cholestasis 
were found. 
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9.2.4 Discussion 
The nephrotoxic and hepatotoxic side effects due to cyclosporin A 
administration as observed in clinical studies in which transplantation of 
allogeneic bone marrow, kidney and liver was performed varied among 
different patients. The effects observed cannot be related to a common 
pathogenetic mechanism. 
Data on reversible increases in blood urea and creatinine in clinical trials (7, 
19, 28) and animal studies (34) suggest that the nephrotoxicity of 
cyclosporin A is due to a direct tubular effect (21, 32). 
The nephrotoxic effect appears to be dose-dependent; it has been observed 
with doses as low as 5.2 mg. kg" daily in recipients of renal allografts and 11 
to 20 mg.kg daily after liver allotransplantation (22). 
Several reports deal with morphological changes in tubules. These include 
an increase in the number of lysosomes, vacuolization and necrosis of 
epithelial cells, particularly of the proximal convoluted tubules (7, 31). 
In the rat, similar changes and, in addition, cytosegregation could be 
induced only with relatively high doses of 25 to 100 mg. kg" every 48 hours 
(33, 34). 
In contrast, biopsies of renal allografts and of kidneys of patients treated 
with cyclosporin A for relapsing polyneuritis showed neither tubular nor 
glomerular changes (8, 32), probably because of a mannitol induced 
diuresis effected largely to avoid the nephrotoxic side effects of cyclo-
sporin A (9). 
In the present study on nephrotoxicity of cyclosporin A in Wistar rats (30 
mg. kg" , S.C. on alternate days for 24 to 103 days), only the increase in 
lysosomes of tubular epithelial cells could be confirmed, taking into account 
the nonspecific nature of this change. An increased number of lysosomes, 
vacuolization of tubular epithelial cells and cytosegregation have been 
observed in instances of enhanced cellular turnover, for instance, in mice 
suffering from experimentally induced malaria (15). 
Unexplained are severe vascular lesions resulting in the thrombosis of 
glomerular capillaries and vessels of the vascular pole and of local fibrin 
deposits at the BM, intimai sclerosis of larger arteries and hyaline deposits 
in arterioles (7, 31). While the localized thrombotic events resemble the 
third type of the Shwartzman reaction (26), the interstitial arterial changes 
may be caused by arterial hypertension developing in Shulman's patients 
(31). 
Organ-dependent intravascular coagulation may result from deposition of 
immune complexes and/or endothelial damage secondary to activation of 
complement Calne (9) stressed that patients treated with cyclosporin A 
alone are capable of mounting a more vigorous humoral response as 
assessed by immunoglobulin concentrations than are those treated with 
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cyclosporin A and corticosteroids or conventional immunosuppressive 
agents. This would facilitate the formation of immune complexes in the 
presence of a circulating antigen and result in the activation of the classic 
pathway of the complement cascade. Indeed, Isenberg (20) reported on a 
decrease in esterase CI inhibitor secondary to cyclosporin A administra-
tioa Calne (7) also suggested that cyclosporin A might act as a hapten 
causing immunological damage to basement membranes. 
Hows (19) suggested a salt retaining effect of cyclosporin A as judged by the 
propensity of his patients to develop a fluid overload. 
Since the Na /K imbalance may be susceptible to vacuolar tubular 
damage and salt retention may be caused by changes in the renin/angio-
tensin system, the present findings of the augmentation of granular 
epitheloid cells in the afferent arterioles gain in significance. 
It is generally agreed that the granular epitheloid cells of the preglomerular 
arterioles are the main sources of renin ora renin-like substance(25,35). In 
the human and particularly in the rat kidney, the proliferation of granular 
epitheloid cells has frequently been associated with the development of 
arterial hypertension; it has also been observed in the Masugi nephritis 
model. 
In the Wistar rat, mesangiosclerosis in the absence of pronounced 
augmentation of granular epitheloid cells is a common disease of old age and 
a cause of the death of the animals (18). However, the matter is more 
complex, since the renin/ angiotensin/aldosterone system is also influenced 
by prostaglandins (23). 
Further studies are therefore required to elucidate whether cyclosporin A is 
directly toxic to renal tubules or whether toxicity is indirectly mediated 
through luxation of the renin / angiotensin / aldosterone / prostaglandin 
system. It is obvious that extrapolation of results obtained from observations 
in one strain of rats to man can be made only with great care (33). 
The present study, however, could be extended to investigate whether 
progression or reversibility of the renal arteriolar and mesangial changes 
will occur after termination of cyclosporin A treatment In addition, the 
influence of the prior administration of cyclophosphamide and ionizing 
radiation could be taken into account 
The results of these studies may offer a better insight into the pathogenesis 
of the late effects due to the administration of cyclosporin A. 
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CHAPTER 10 
POTENTIAL APPLICATIONS 
OF THE DEVELOPED MODEL 
The main purpose of the work presented in this thesis was to develop an 
animal model for human tumor xenografts with the objectives listed in 
Chapter 1.4. The conditioned Wistar rat model was developed and is 
introduced for the first time (Fuks Z, personal communication, June 1982). 
Careful review of the recent literature did not reveal an in vivo model similar 
to iL 
The experiments reported in this volume are only the beginning of a long 
series of similar ones for future research. Up to now, attention has been 
focused on the standardization, validation and initial understanding of the 
immunological mechanisms involved 
There is now need for a thorough evaluation of the characteristics of the 
system in order that its potential applications can be determined. 
For example, the exact interaction between cyclosporin A and pretreatment 
with cyclophosphamide and total lymphoid irradiation still needs to be 
elucidated. 
There are many possibilities for the use of the conditioned Wistar rat model 
in future research. 
1. Applications related to testing cancer treatment modalities. Human 
tumor xenografts can be tested with respect to: 
a) response to irradiation, dose response, effect of fractionation, dose 
rate, split course of treatment, radiobiological effectiveness; 
b) response to combinations of irradiation, radiosensitizers, radiopro-
tectors, hyperthermia and cytotoxic drugs; 
c) response to chemotherapy as regards sensitivity and dose response 
and combination with hyperthermia. 
Individual human tumor xenografts can be tested for sensitivity to single 
or multiple therapeutic agents. In addition to short-term in vitro studies, 
longterm in vivo studies could supply added information for future 
second line-treatment 
The model can also be used to establish human tumor cell lines for the 
screening and testing of new antineoplastic compounds. 
2. Applications related to studies of human tumor biology might include: 
a) study of factors involved in the growth of tumor cells and tumor 
stroma; 
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b) investigation of factors which can lead to changes in cell kinetics 
including synchronization, proliferation, differentiation; 
c) elucidation of mechanisms of tumor vascularization, development of 
tumor/host blood supply and tumor microcirculation; 
d) investigation of the possible interaction of two different tumor types 
growing simultaneously in the same host 
3. Applications related to hosVtumor xenograft interactions: 
a) extensive investigation of the mechanisms involved in xenograft 
rejection; 
b) manipulation of the host immune response following the growth of 
human tumor xenografts, this might lead to the development and 
isolation of specific tumor antibodies which may be used for 
diagnostic and therapeutic purposes. 
Another potential application of the immunosuppressive protocol is in the 
treatment of patients with autoimmune diseases. 
The above-mentioned are only some of many other possibilities and 
ramifications of research areas. 
Applications in the area of organ transplantation and adaptation of the 
immunosuppressive protocol described to other animal species are beyond 
the scope of this thesis. 
SUMMARY 
Chapter 1 In the introduction, different in vivo and in vitro models for 
human xenograft are described and the advantages and disad­
vantages are critically reviewed The aim of the present 
investigation is stated 
Chapter 2 A brief outline of the basic immunological aspects of the 
Wistar rat is presented This is followed by a general descrip­
tion of methods applied for the induction of immunosuppres­
sion. The immunological effects of cyclophosphamide, total 
lymphoid irradiation and cyclosporin A are outlined. 
Chapter 3 The technical and dosimetric aspects of total lymphoid irradia­
tion (TLI) in the Wistar rat are evaluated 
Information obtained from anatomical dissections, radionu­
clide imaging of the spleen, lymphography and chromolym-
phography was used to standardize the localization of lymph 
nodes, the thymus and the spleen. A practical advantage was 
found in the simultaneous irradiation through two portals cut 
out in a lead plate. 
The two portals encompassed the lymphoid tissue above and 
below the diaphragm. A specially designed masonite phantom 
was used to determine the dose distribution in the simulated 
target volumes. Ionization chamber dosimetry, thermolumi­
nescence dosimetry and film densitometry were used for deter­
mining exposure and absorbed dose. Irradiation was perfor­
med with 250 kV X rays (HVL 3.1 mm Cu). 
The dose rate was regulated by adjusting the treatment 
distance. The dose inhomogeneity measured in the target 
volumes varied between 80-100%. The side scatter dose to 
nontarget tissues under the shielded area between the two 
portals ranged between 20-30%. The technique and dosimetry 
of total lymphoid irradiation in Wistar rats are standardized 
and validated 
Chapter 4 Several hematologic and immunologic parameters in the 
animal model were investigated 
These included hemoglobin concentration, hematocrit, the 
number of leucocytes, erythrocytes, platelets, lymphocytes 
and monocytes, serum IgG levels, phytohemagglutinin and 
concanavalin A responses of peripheral lymphocytes and the 
percentage of peripheral В lymphocytes. 
Standard values were determined for reference. 
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Chapter 5 Three-month-old male Wistar rats were conditioned by treat­
ment with cyclophosphamide (4 X 10 mg. kg" ) and total 
lymphoid irradiation (900 cGy, dose rate 20 cGy.min ). 
The immunosuppression was monitored by lymphocyte counts, 
serum IgG determinations, PHA and Con A responses, 
proportion of В cells and histopathological studies of the 
lymphoid organs. 
At eight days after treatment the lymphocyte counts, IgG 
levels and PHA and Con A values were decreased 
Mitotic activity started in the depleted В and Τ cell areas of the 
peripheral lymphatic organs at two weeks after treatment, 
There was 94% graft take of the mouse C22LR osteosarcoma 
The optimum time for tumor xenograft transplantation was 4 
days after treatment The growth duration was 11 days and this 
was followed by regression up to day 21. 
Chapter 6 Wistar rats treated with cyclophosphamide, total lymphoid 
irradiation (TLI) and/or cyclosporin A (CSA) develop a state 
of immune suppression permitting the growth of tumor xeno­
grafts. Experiments were carried out on the developed model to 
investigate the growth patterns of a mouse osteosarcoma and a 
human colon adenocarcinoma. The combination of cyclophos­
phamide and CSA permitted a limited period of growth of the 
mouse osteosarcoma with a tumor take rate of 66%. 
No takes were observed with the human adenocarcinoma. 
The combination of cyclophosphamide and TLI resulted in a 
period of immunosuppression followed by recovery of the 
immune status. During the period of immunisuppression, 
tumor xenografts showed a 94% take rate. The most efficient 
immunosuppression was achieved by a combination of cyclo­
phosphamide, TLI and CSA administered on alternate days. 
Wistar rats subjected to this treatment showed prolonged tole­
rance to mouse osteosarcoma and human adenocarcinoma 
xenografts. 
There was no alteration in the tumor doubling time or 
histological morphology of the xenografts in the adapted host 
as compared with those in the donor tumors. The tumor growth 
curve showed a pattern of initial growth and a period of 
stagnation followed by a steady but slower growth phase. 
Chapter 7 Changes in the thymus reflect the condition of the T-dependent 
areas in peripheral lymphatic organs. 
The higher the degree of involution of the thymus, the more 
depleted is the paracortical area (lymph node), the periarterio-
lar lymphatic sheath (spleen) and the interfollicular area 
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(Peyer's patches). There was no direct correlation, however, 
between the condition of the T-dependent regions and the 
immune reactivity against the tumor xenograft. 
Although repeated thymus irradiation resulted in severe depo­
pulation of these areas, the xenograft rejection was accelera­
ted. In contrast, animals bearing proliferating xenografts for up 
to 103 days exhibited moderately dense cell accumulations in 
portions of T-dependent areas. 
Recovery of immune reactivity was associated with a detec­
table increase in lymphocyte recirculation rates and, some­
what later, with the formation of germinal centers. 
Chapter 8 The histological characteristics of the donor mouse osteosar­
coma and the human adenocarcinoma were fully maintained 
after xenotransplantation in the immunosuppressed murine 
host Rates of mitotic proliferation were consistent for the 
adenocarcinoma xenograft even after 103 days of growth in the 
xenogeneic recipient In instances of insufficient immunosup­
pressive management, the grafted tumors were rejected The 
immunological destruction, however, occured notably in the 
absence of lymphocyte infiltratioa 
The primary immune reaction appears to be a complement-
dependent humoral response directed against the endothelium 
of the tumor vessels. It is suggested that, as a result of ischemic 
necrosis of portions of the tumor, released tumor antigens 
trigger a subsequent lymphocytic and plasma cellular reaction 
in tissues around the necrotic xenograft. 
The pattern of graft rejection reflects to some extent the 
changes simultaneously occurring in peripheral lymphatic or­
gans. 
Chapter 9 Histological study of the bladder mucosa of the rat model 
showed no evidence of urothelial toxicity due to cyclophos­
phamide (4 X 10 mg.kg ). 
Tissue examination for possible toxic effects of cyclosporin A 
on the kidney and liver was made. 
There was no evidence of nephrotoxic side effects of cyclo­
sporin A such as glomerular capillary thrombosis and damage 
to tubular epithelium. There was an increase in tubular 
epithelial lysosomes, but this was nonspecific. 
A drastic increase in gramil; г epitheloid cells of afferent 
glomerular vessels suggests possible changes in the renin/ 
angiotensin II/aldosterone system. Combination of cyclo­
sporin A with the pretransplant conditioning protocol (cyclo­
phosphamide, 4X10 mg. kg and total lymphoid irradiation, 
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900 cGy, (1=20 cGy.min ) resulted in mesangiosclerosis 
and sclerosis of the tubular membrane of several nephrons after 
103 days. 
The main liver changes secondary to cyclosporin A were the 
accumulation of fat in scattered hepatocytes and slight inter-
stitial fibrosis after 103 days. 
Chapter 10 Suggestions for future applications of the model are proposed 
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SAMENVATTING 
Hoofdstuk 1 In deze inleiding worden de verschillende in vivo en in 
vitro humane xenograft modellen met hun voor- en nadelen 
beschreven. Het doel van het onderzoek wordt uiteen gezet. 
Hoofdstuk 2 Geeft een beknopt overzicht van het immunologisch 
systeem van de Wistar-rat; hierop volgt een algemene 
beschrijving van de methoden die worden toegepast om een 
immunosuppressie te bereiken. De immunologische effecten 
van cyclophosphamide, bestraling van het lymfatische sy-
steem, en cyclosporine A worden uiteen gezet 
Hoofdstuk 3 Bevat een overzicht van de technische en dosimetrische 
aspecten van de bestraling van het lymfatische systeem bij de 
Wistar-raL Gegevens, verkregen door middel van histolo-
gische ontleding, en door middel van afbeelding van de milt 
met behulp van radionucliden, lymfografie en chromolymfo-
grafie, werden gebruikt voor de localisatie van lymfklieren, 
thymus en milt. 
Om practische redenen werden twee doel-volumina be-
straald via één veld en een looddiafragma met twee uitsparin-
gen; deze laatste corresponderen met het lymfatische sy-
steem boven en onder het diafragma. Het isodosenpatroon 
van de bestralingsvelden werd bepaald in een masoniet 
fantoom. Daarbij werd voor meting van de geabsorbeerde 
dosis gebruik gemaakt van ionisatiekamer-, thermolumine-
scentie- en fïlmdosimetrie. De dosis in het doelvolume 
varieerde van 80 tot 100% van het maximum. De verstrooide 
dosis in het weefsel buiten het doelgebied, onder de loodaf-
scherming, bedroeg 20 tot 30% van de maximale dosis in het 
doelgebied. De gebruikte straling was 250 kV röntgenstraling 
met een halfwaarde dikte van 3,1 mm Cu. Het dosistempo 
werd ingesteld door de bestralingsafstand aan te passea 
De beschreven bestralings- en dosimetrische technieken 
bleken zeer bruikbaar en werden als standaardmethoden 
toegepast 
Hoofdstuk 4. De volgende hematologische en immunologische parame-
ters werden onderzocht in het diermodel: hemoglobinecon-
centratie, hematocriet, de aantallen leucocyten, erythrocy-
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ten, trombocyten, lymfocyten en monocyten, de IgG spiegels 
in het serum d'. ,.' y.ohemagglutinine(PHA)enconcanava-
line A (Con A) responsies van de perifere lymfocyten en het 
percentage perifere В lymfocyten. 
Standaard referentiewaarden werden bepaald. 
Hoofdstuk 5. Wistar-ratten van drie maanden oud werden voorbehan-
deld met cyclophosphamide (4X10 mg.kg ) en bestraling 
van het lymfatische systeem (900 cGy, dosistempo 20 cGy. 
min" ). 
De mate van immunosuppressie werd nagegaan aan de hand 
van meting van het aantal lymfocyten, de serum IgG spiegel, 
de PHA en Con A responsiewaarden en het percentage B-
cellen, en tevens door middel van histopathologische studies 
van de lymfatische organen. Acht dagen na de behandeling 
waren het aantal lymfocyten, het IgG niveau en de PHA- en 
Con A-waarden sterk verminderd. Mitose-activiteit ontstond 
twee weken na de behandeling in de ontvolkte B- en T-cel 
gebieden van de perifere lymfatische organen. In 94% van de 
gevallen was de implantatie van het osteosarcoomC22LR 
van de muis succesvol. Het meest geschikte tijdstip voor 
transplantatie van de xenograft-tumor is vier dagen na de 
voorbehandeling. Gedurende elf dagen groeide de xenograft-
tumor, daarna volgde een periode van regressie tot de 
éénentwintigste dag. 
Hoofdstuk 6. Het immuunsysteem van de Wistar-ratten, die zijn voorbe-
handeld met cyclophosphamide, bestraling van het lymfati-
sche systeem en/of cyclosporine A, is dermate onderdrukt 
dat de groei van xenograft-tumoren mogelijk blijkt 
Met het ontwikkelde model werden experimenten uitgevoerd 
om het groeipatroon van het osteosarcoom van de muis en het 
humane adenocarcinoom van het colon te bestuderen. Com-
binatie van cyclophosphamide en cyclosporine A gaf een 
beperkte groeiperiode van het osteosarcoom van de muis te 
zien. In 66% van de gevallen sloeg het tumortransplantaat 
aan. In geval van het humane adenocarcinoom was geen 
enkele tumorimplantatie succesvol. 
Combinatie van cyclophosphamide en bestraling van het 
lymfatische systeem resulteerde in een periode van immuno-
suppressie, die door herstel van het immunologische systeem 
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werd gevolgd Tijdens de periode van immunosuppressie was 
de xenograft-tumorimplantatie (osteosarcoom) in 96% suc-
cesvol. De meest effectieve immunosuppressie werd bereikt 
door een combinatie van cyclophosphamide, bestraling van 
het lymfatische systeem en toediening om de andere dag van 
cyclosporine A. De Wistar-ratten die hiermee werden behan-
deld, toonden een verlengde tolerantieperiode voor muis-
osteosarcoom en humaan-adenocarcinoom-xenograften. 
In het diermodel werd geen verandering van de verdubbel-
ingstijd of van de histologische morfologie van de xenograften 
waargenomen in vergelijking met die van de donortumoren. 
De tumorgroeicurve laat aanvankelijk een groei zien, gevolgd 
door stagnatie, waarna een periode van blijvende maar 
langzamer verlopende groei volgt. 
Hoofdstuk 7. De veranderingen in de thymus weerspiegelen de toestand 
van de T-afhankelijke gebieden in de perifere lymfatische 
organen. Hoe sterker de involutie van de thymus, des te meer 
ontvolkt zijn het paracorticale gebied (lymfklier), de periar-
teriolaire lymfatische schede (milt) en het interfolliculaire 
gebied (plaques van Peyer). Er was echter geen direkt 
verband tussen de toestand van de T-afhankelijke gebieden 
en de immunologische reactiviteit tegen de tumor xenograft. 
Hoewel herhaalde thymus bestralingen resulteerden in sterke 
ontvolking van deze gebieden werd de xenograft-afstoting 
versneld. Anderzijds waren in dieren welke prolifererende 
xenograften tot 103 dagen accepteerden, bescheiden celop-
hopingen te vinden in delen van T-afhankelijke gebieden. 
Herstel van de immunologische reactiviteit bleek gepaard te 
gaan meteen aantoonbare verhoging van de aantalen recircu-
lerende lymfocyten en enige tijd later met de vorming van 
kiemcentra 
Hoofdstuk 8. De histologische kenmerken van het donormuisosteosar-
coom en het humane adenocarcinoom werden volledig 
gehandhaafd na xenotransplantatie in de geïmmunosuppres-
seerde gastheer. De mate van mitose-activiteit van de 
adenocarcinoom xenograft wijzigde zich niet, zelfs niet na 
103 dagen groei in de xenogenetische recipiënt 
Op het moment van onvoldoende immunosuppressie werd de 
getransplanteerde tumor afgestoten. De immunologische 
destructie geschiedde in afwezigheid van lymfocytaire infil-
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tratie. De primaire immunologische reactie schijnt een com-
plement-afhankelijke humorale respons te zijn, gericht tegen 
de endotheelcellen van de tumorvaten. De veronderstelling 
wordt geuit dat tumor-antigenen, vrijgekomen als gevolg van 
ischemische necrose van delen van de tumor, een lymfocy-
taire en plasmacellulaire reactie in de weefsels rond de 
necrotische xenograft oproepen. 
Het patroon van de graftafstoting weerspiegelt enigermate de 
veranderingen welke tegelijkertijd in de perifeer lymfatische 
organen plaatsvinden. 
Hoofdstuk 9. Histologische bestudering van de blaasmucosa van de ge-
bruikte ratten leverde geen aanwijzingen op voor slijmvlies-
beschadigingen ten gevolge van cyclophosphamide (4X10 
mg. kg" ). Ook nier en lever werden histologisch onderzocht 
op mogelijke schadelijke effecten van cyclosporine A. Er 
waren geen aanwijzingen voor nephrotoxische neveneffec-
ten van het cyclosporine A, zoals glomerulaire capillaire 
trombose en beschadiging van het tubulaire epitheel. Er was 
een toename van lysosomen in het epitheel van de tubuli, 
maar deze was niet specifiek. 
De aanzienlijke toename van granulaire epithelioïde cellen 
van de afferente glomerulaire vaten doet de mogelijkheid van 
veranderingen veronderstellen in het renine-angiotensine II-
aldosteronsysteem. 
Combinatie van cyclosporine A met het voorbehandelings-
protocol (cyclophosphamide, 4 X 10 mg.kg" , en bestraling 
van het lymfatische systeem, 900 cGy, dosistempo 20 
cGy.min ), veroorzaakte na 103 dagen mesangiosclerose en 
sclerose van de tubulus-membranen van verscheidene 
nephronen. De belangrijkste veranderingen in de lever ten 
gevolge van cyclosporine A waren, na 103 dagen, vetopho-
pingen in verspreide hepatocyten, en een beperkte intersti-
tiële fibrose. 
Hoofdstuk 10 Bevat voorstellen voor toekomstige toepassingen van het 
model. 
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Stellingen behorend bij 
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MODEL FOR TUMOR 
XENOTRANSPLANTATION 
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STELLINGEN 
I 
In het beschreven diermodel symboliseert het potentiêrend effect van de toepassing van cyclo-
fosfamide, die gevolgd wordt door totale lymfklierbestraling, de samenwerking tussen de 
medisch oncoloog en de radiotherapeut. 
Π 
Bij totale lymfklierbestraling van de muis is de dosis strooistraling in de afgeschermde gebieden 
relatief hoger dan bij de rat 
ΠΙ 
In het beschreven diermodel lijkt cyclosporine A geen antineoplastisch effect te bezitten. 
IV 
Bij het toepassen van inhomogeniteitscorrecties bij de berekening van de dosisverdeling van 
megavolt röntgenbundels is het van primair belang de verschillende dichtheden van het 
doorstraalde gebied te kennen. 
De keuze van het te gebruiken correctie-algoritme is van secundair belang. 
J.R. Cunningham, Computer Assisted Treatment Planning in Radiotherapy, Hamburg 7 
september 1982. 
V 
Additieve radiotherapie na een subtotale resectie van het craniopharyngioma verlengt de 
recidiefvrije periode, verkleint de kans op recidief; visusstoomissen en/of endocriene 
stoornissen lijken niet progressief. 
VI 
Bij een wondabces na een mamma-amputatie moet men bedacht zijn op de aanwezigheid van 
een Campylobacter jejuni. 
VII 
Bij aanwezigheid van dubbelzijdige simian en/of Sidney buigplooien bij het jonge kind dient de 
arts bedacht te zijn op de mogelijke aanwezigheid of ontwikkeling van een leukemie of een 
embryonale tumor. 
Cancer 43: 749-759, 1979. 
ПІ 
Het winnen van levensjaren voor de oncologische patient gaat gepaard met verlies van 
levenstijd voor zijn naaste omgeving. 
EX 
De behandeling van de maligniteit kan alleen optimaal in teamverband plaatsvinden, soms ten 
nadele van de belangen van de patient als mens. 
Het maatschappelijk perspectief voor hen die aan het einde van de eerste fase (TFS) van hun 
medische opleiding zullen zijn gekomen, zal beperkt zijn. 
XI 
De hogere beroepsopleiding van studenten uit ontwikkelingslanden dient niet plaats te vinden 
aan opleidingsinstituten in het Westen, maar door detachering in ontwikkelingslanden van 
Westerse docenten. 
XII 
Ter verhoging van de rundvleesproductie verdient het aanbeveling in ontwikkelingslanden de 
maiscultuur ten dele te vervangen door de verbouw van sorghum. 
J. v. Arkel, NRC Handelsblad, 29 september 1982 
XIII 
Dragers van Nederlandse wetenschappelijke titels zouden beter via een internationale 
titulatuur betiteld kunnen worden. 



